[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1449
1. Lou YJ, Qian WB, Jin J: Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma; 2007 Jul;48(7):1400-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myeloma cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide (MTT) assay.
  • Apoptotic cells and cell cycle were evaluated by flow cytometry.
  • We found that HHT significantly inhibited the proliferation of human multiple myeloma (MM) cell lines and tumor cells from patients with relapsed refractory MM in a dose-dependent manner.
  • [MeSH-major] Apoptosis / drug effects. Cell Division / drug effects. Harringtonines / pharmacology. Multiple Myeloma / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Caspases / analysis. Cell Line, Tumor. Dexamethasone / pharmacology. Drug Synergism. Humans. Poly(ADP-ribose) Polymerases / analysis

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613769.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Harringtonines; 6FG8041S5B / homoharringtonine; 7S5I7G3JQL / Dexamethasone; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases
  •  go-up   go-down


2. Madry K, Dwilewicz-Trojaczek J, Suleiman W, Paszkowska-Kowalewska M, Ziarkiewicz-Wróblewska B: [Angiogenesis in bone marrow of myelodysplastic syndrome patients]. Pol Arch Med Wewn; 2007 Apr;117(4):25-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We have measured bone marrow microvessel density (MVD) in 43 myelodysplastic syndrome (MDS) patients and in 10 subjects of group control--10 lymphoma patients (their bone marrow was free of disease).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia, Refractory, with Excess of Blasts / blood. Anemia, Refractory, with Excess of Blasts / pathology. Antigens, CD31 / blood. Antigens, CD34 / blood. Female. Humans. Immunohistochemistry. Leukemia, Myelomonocytic, Chronic / blood. Leukemia, Myelomonocytic, Chronic / pathology. Male. Microcirculation / pathology. Middle Aged


3. Weigand K, Ganten TM, Andrulis M, Stremmel W, Sauer P, Schaible A: Chronic anemia masking a primary large B-cell lymphoma of the small intestine, finally diagnosed by double-balloon enteroscopy. Endoscopy; 2008 Sep;40 Suppl 2:E149
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic anemia masking a primary large B-cell lymphoma of the small intestine, finally diagnosed by double-balloon enteroscopy.
  • [MeSH-major] Anemia, Refractory / diagnosis. Capsule Endoscopy / methods. Jejunal Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633862.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood; 2008 Sep 15;112(6):2261-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
  • Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphoma in human subjects.
  • We report the results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T-cell receptor and neomycin resistance gene.
  • Seven patients received a total of 20 T-cell infusions, with minimal toxicities.
  • These results show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach.
  • [MeSH-major] Antigens, CD20 / genetics. Immunotherapy, Adoptive / methods. Lymphoma, Mantle-Cell / therapy. Lymphoma, Non-Hodgkin / therapy. T-Lymphocytes / transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytotherapy. 2003;5(2):131-8 [12745575.001]
  • [Cites] Nat Med. 2003 Mar;9(3):279-86 [12579196.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):577-86 [15093188.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):2143-50 [15265951.001]
  • [Cites] Nature. 1979 Oct 11;281(5731):490-1 [386133.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Nat Med. 1996 Feb;2(2):216-23 [8574968.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):1974-81 [8683227.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Biol Blood Marrow Transplant. 1998;4(2):75-83 [9763110.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3535-42 [15304387.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2294-302 [16282341.001]
  • [Cites] Immunol Rev. 2006 Jun;211:154-63 [16824125.001]
  • [Cites] Immunol Rev. 2006 Jun;211:214-24 [16824130.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(4):737-55 [16997180.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):825-33 [17299405.001]
  • [Cites] Hum Gene Ther. 2007 Aug;18(8):712-25 [17685852.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):294-305 [18060041.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5530-6 [18411419.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] Am J Clin Pathol. 2000 Jun;113(6):838-50 [10874885.001]
  • [Cites] Mol Ther. 2000 Jan;1(1):49-55 [10933911.001]
  • [Cites] Int J Hematol. 2001 Feb;73(2):213-21 [11372734.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1288-94 [11870171.001]
  • [Cites] Blood. 2002 May 1;99(9):3158-62 [11964278.001]
  • [Cites] J Exp Med. 2002 Jun 17;195(12):1523-32 [12070280.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5780-6 [12421958.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [CommentIn] Blood. 2008 Sep 15;112(6):2172-3 [18779394.001]
  • (PMID = 18509084.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00012207
  • [Grant] United States / NCI NIH HHS / CA / R01 CA092302; United States / NCI NIH HHS / CA / R21 CA-117131-01A; United States / NCRR NIH HHS / RR / M01-RR-00 037; United States / NCI NIH HHS / CA / R21 CA117131; United States / NCI NIH HHS / CA / R01 CA92302
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20
  • [Other-IDs] NLM/ PMC2532803
  •  go-up   go-down


5. Biscardi M, Teodori E, Caporale R, Budriesi R, Balestri F, Scappini B, Gavazzi S, Grossi A: Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk Res; 2006 Jan;30(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of refractory disease is often associated with the overexpression of multidrug resistance (MDR) proteins, especially in several hematological malignancies, such as acute myeloid leukemias (AML), multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).
  • Cytotoxicity (WST-1 methods) and functional (calcein-acetoxymethyl (Calcein-AM)) assays were performed on a resistant cell line K-562/doxR and on the mononuclear cells (MNCs) of patients with AML.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibiotics, Antineoplastic / pharmacology. Antibiotics, Antineoplastic / therapeutic use. Antibiotics, Antineoplastic / toxicity. Aorta / drug effects. Aorta / metabolism. Drug Evaluation, Preclinical. Female. Guinea Pigs. Heart Atria / drug effects. Heart Atria / metabolism. Humans. Idarubicin / pharmacology. Idarubicin / therapeutic use. Idarubicin / toxicity. K562 Cells. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / metabolism. Multiple Myeloma / pathology. Organ Culture Techniques

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061283.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Antibiotics, Antineoplastic; 0 / P-Glycoprotein; CJ0O37KU29 / Verapamil; ZRP63D75JW / Idarubicin
  •  go-up   go-down


6. Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N: Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma; 2010 Dec;51(12):2222-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between 2005 and 2008, we conducted separate phase II clinical testing of three distinct anti-VEGF therapies for patients with relapsed/refractory CLL.
  • Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Leuk Res. 2008 Apr;32(4):593-7 [17928052.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Leuk Lymphoma. 2009 Jan;50(1):62-7 [19125384.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Br J Haematol. 2009 Sep;146(6):660-4 [19604237.001]
  • [Cites] Blood. 2010 Jan 28;115(4):846-9 [19965686.001]
  • [Cites] Blood. 2010 Jun 3;115(22):4447-54 [20164467.001]
  • [Cites] Leuk Lymphoma. 2010 Jul;51(7):1351-3 [20496991.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):353-6 [20182346.001]
  • [Cites] Clin Cancer Res. 2010 Jul 1;16(13):3390-8 [20570929.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):605-10 [10583266.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1414-8 [10942237.001]
  • [Cites] Leuk Res. 2001 Apr;25(4):279-85 [11248324.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):795-9 [11309324.001]
  • [Cites] Leukemia. 2002 May;16(5):911-9 [11986954.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3344-51 [12384436.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):243-8 [14687619.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):965-70 [10070898.001]
  • [Cites] Leukemia. 2005 Apr;19(4):513-23 [15703780.001]
  • [Cites] Leukemia. 2005 Apr;19(4):524-30 [15674425.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4813-9 [15731179.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Leukemia. 2006 Apr;20(4):583-9 [16467866.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):174-85 [16616064.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Leukemia. 2007 Jan;21(1):44-52 [16990761.001]
  • [Cites] Vnitr Lek. 2007 Nov;53(11):1171-6 [18277626.001]
  • (PMID = 21054149.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CM62205; United States / NCI NIH HHS / CM / N01-CM62207; United States / NCI NIH HHS / CM / N01 CM062205; United States / NCI NIH HHS / CA / U24 CA114740; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CM / N01-CM62205; United States / NCI NIH HHS / CA / CA114740; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / N01CM62207; United States / NCI NIH HHS / CA / CA116237; United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CM / N01 CM062207; United States / NCI NIH HHS / CA / R01 CA116237; United States / NCI NIH HHS / CA / N01 CA015083
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / Quinazolines; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; NQU9IPY4K9 / cediranib; V99T50803M / sunitinib
  • [Other-IDs] NLM/ NIHMS550827; NLM/ PMC3928074
  •  go-up   go-down


7. Cesaro S, Pillon M, Visintin G, Putti MC, Gazzola MV, D'Amore E, Scarzello G, Zanesco L, Messina C, Rosolen A: Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series. Eur J Haematol; 2005 Jul;75(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series.
  • OBJECTIVES: The use of allogeneic stem cell transplantation in NHL patients is not yet clearly defined, especially in children and adolescents, but this option offers the advantages of a tumor-free graft and the possible induction of a graft-vs.-tumor effect.
  • PATIENTS AND METHODS: We report the results of four consecutive pediatric patients affected by anaplastic large cell lymphoma (ALCL) and treated with allogeneic stem cell transplantation from an unrelated donor.
  • CONCLUSIONS: The increasing number of volunteer bone marrow donors and the reduced toxicity of unrelated stem cell transplantation, especially in children, make this therapeutic option worth more extensive investigation in the treatment of high-risk failure ALCL, although more data is needed to evaluate the long-term benefits.
  • In this regard, the presence of factors predictive of worst outcome such as an early relapse (within 12 months from diagnosis), a refractory or relapsing ALCL and the persistent detection on blood or bone marrow of nucleophosmin-anaplastic lymphoma kinase protein (NPM-ALK) transcript may help select the patients eligible to allogeneic related or unrelated stem cell transplantation.
  • [MeSH-major] Bone Marrow Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy


8. Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS: Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma; 2010 May;51(5):789-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
  • Autologous stem cell transplant (ASCT) is the standard of care for patients with relapsed diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367136.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


9. Yi YS, Chung JS, Song MK, Shin HJ, Seol YM, Choi YJ, Cho GJ, Lee GW, Moon JH, Hwang IH, Ahn KH, Lee HS, Shin KH, Hwang JM: The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma. Korean J Hematol; 2010 Sep;45(3):188-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-six patients with refractory or relapsed MM who underwent chemotherapy with bortezomib were included in the study.
  • CONCLUSION: Bortezomib itself might act as a risk factor for HZ by inhibiting cell-mediated immunity, and patients with low ALC at the time of bortezomib treatment initiation were at greater risk of HZ during bortezomib treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • [Cites] J Clin Virol. 2010 May;48 Suppl 1:S2-7 [20510263.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Cancer Control. 2003 Sep-Oct;10(5):361-9 [14581890.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] Lancet. 1974 Jun 22;1(7869):1293 [4134180.001]
  • [Cites] Eur J Immunol. 2006 Mar;36(3):681-9 [16479541.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2165-72 [16772605.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2767-72 [17148584.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3557-60 [17690257.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1160-5 [18326520.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Aug;8(4):237-40 [18765311.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4784-90 [18711175.001]
  • [Cites] Int J Hematol. 2009 Apr;89(3):342-7 [19296199.001]
  • [Cites] Drugs. 2009;69(7):859-88 [19441872.001]
  • [Cites] Leuk Res. 2009 Dec;33(12):1615-8 [19773080.001]
  • [Cites] Clin Infect Dis. 2009 Oct 15;49(8):1211-25 [19769539.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1151-8 [12133934.001]
  • (PMID = 21120208.001).
  • [ISSN] 2092-9129
  • [Journal-full-title] The Korean journal of hematology
  • [ISO-abbreviation] Korean J Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2983043
  • [Keywords] NOTNLM ; Herpes zoster / Multiple myeloma / Protease inhibitors
  •  go-up   go-down


10. Health Quality Ontario: Extracorporeal photophoresis: an evidence-based analysis. Ont Health Technol Assess Ser; 2006;6(6):1-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the effectiveness, safety and cost-effectiveness of extracorporeal photophoresis (ECP) for the treatment of refractory erythrodermic cutaneous T cell lymphoma (CTCL) and refractory chronic graft versus host disease (cGvHD).
  • BACKGROUND: CUTANEOUS T CELL LYMPHOMA: Cutaneous T cell lymphoma (CTCL) is a general name for a group of skin affecting disorders caused by malignant white blood cells (T lymphocytes).
  • Cutaneous T cell lymphoma is relatively uncommon and represents slightly more than 2% of all lymphomas in the United States.
  • Cutaneous T cell lymphoma has an annual incidence of approximately 0.4 per 100,000 and it mainly occurs in the 5(th) to 6(th) decade of life, with a male/female ratio of 2:1.
  • Mycosis fungoides is an indolent lymphoma with patients often having several years of eczematous or dermatitic skin lesions before the diagnosis is finally established.
  • CHRONIC GRAFT VERSUS HOST DISEASE: Allogeneic hematopoietic cell transplantation (HCT) is a treatment used for a variety of malignant and nonmalignant disease of the bone marrow and immune system.
  • TREATMENT:   CUTANEOUS T CELL LYMPHOMA: The optimal management of MF is undetermined because of its low prevalence, and its highly variable natural history, with frequent spontaneous remissions and exacerbations and often prolonged survival.
  • Treatment of advanced stage (IIB-IV) MF usually consists of topical or systemic therapy in refractory or rapidly progressive SS.
  • Bone marrow transplantation and peripheral blood stem cell transplantation have been used to treat many malignant hematologic disorders (e.g., leukemias) that are refractory to conventional treatment.
  • Numerous salvage therapies have been considered in patients with refractory cGvHD, including ECP.
  • Due to uncertainty around salvage therapies, Bhushan and Collins suggested that ideally, patients with refractory cGvHD should be entered into clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):207-20 [9486676.001]
  • [Cites] J Am Acad Dermatol. 1996 Oct;35(4):573-9 [8859287.001]
  • [Cites] J Cutan Med Surg. 2003 Jul-Aug;7(4 Suppl):13-7 [12958702.001]
  • [Cites] Cancer. 1988 Oct 15;62(8):1658-61 [3167782.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1217-23 [12714516.001]
  • [Cites] J Am Acad Dermatol. 1992 Sep;27(3):427-33 [1401279.001]
  • [Cites] N Engl J Med. 1987 Feb 5;316(6):297-303 [3543674.001]
  • [Cites] Arch Dermatol. 2002 Oct;138(10):1347-50 [12374541.001]
  • [Cites] J Am Acad Dermatol. 1992 Nov;27(5 Pt 1):729-36 [1430395.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):701-7 [376140.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1404-11 [12663734.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):372-82 [3408055.001]
  • [Cites] Arch Dermatol. 1998 Aug;134(8):1001-5 [9722731.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):253-60 [11174383.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):263-71 [10906649.001]
  • [Cites] Br J Dermatol. 2000 Jan;142(1):16-21 [10651689.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(12):1187-93 [15852025.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1745-52 [11745245.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):935-45 [8959953.001]
  • [Cites] Yale J Biol Med. 1989 Nov-Dec;62(6):629-38 [2534648.001]
  • [Cites] J Cutan Pathol. 1997 May;24(5):286-91 [9194581.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):7-20 [16403088.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2671-7 [7260860.001]
  • [Cites] Ann Intern Med. 1994 Oct 15;121(8):592-602 [8085692.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(6):459-65 [12665841.001]
  • [Cites] Lancet. 1997 Jul 5;350(9070):32-3 [9217723.001]
  • [Cites] Int J Artif Organs. 2000 Jan;23(1):55-62 [12118838.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1298-301 [11520774.001]
  • [Cites] JAMA. 2003 Nov 19;290(19):2599-603 [14625337.001]
  • [Cites] Blood. 1987 Mar;69(3):841-9 [3493044.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):271-5 [16029456.001]
  • [Cites] Arch Dermatol. 2002 Aug;138(8):1054-60 [12164743.001]
  • [Cites] J Am Acad Dermatol. 1993 Apr;28(4):580-4 [8463458.001]
  • [Cites] Lancet. 1997 Sep 20;350(9081):886 [9310623.001]
  • [Cites] N Engl J Med. 1989 Dec 28;321(26):1784-90 [2594037.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):327-36 [14996105.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):54-60 [10863224.001]
  • [Cites] Lancet. 2001 Mar 17;357(9259):820-1 [11265946.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3074-80 [16368882.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):118-27 [12823353.001]
  • [Cites] Clin Exp Dermatol. 2004 May;29(3):231-6 [15115499.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):946-57 [8959954.001]
  • [Cites] Ann N Y Acad Sci. 1991 Dec 30;636:171-7 [1793207.001]
  • [Cites] J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):460-6 [9091480.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):1-5 [16033336.001]
  • (PMID = 23074497.001).
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3379535
  •  go-up   go-down


11. Moskowitz AJ, Moskowitz CH: Controversies in the treatment of lymphoma with autologous transplantation. Oncologist; 2009 Sep;14(9):921-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the treatment of lymphoma with autologous transplantation.
  • High-dose therapy and autologous stem cell transplant (HDT-ASCT) is the standard of care for relapsed and refractory diffuse large B cell lymphoma and Hodgkin's lymphoma; however, the role for HDT-ASCT in the treatment of follicular lymphoma (FL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) is controversial.
  • Allogeneic stem cell transplant remains the only curative treatment option and is appropriate for patients with high bone marrow disease burdens and refractory disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Clinical Trials as Topic. Humans. Lymphoma, Follicular / therapy. Lymphoma, Mantle-Cell / therapy. Lymphoma, T-Cell / therapy. Neoplasm Recurrence, Local. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4365-70 [19652064.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):793-800 [12614212.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Ann Oncol. 2003 May;14(5):737-44 [12702528.001]
  • [Cites] Blood. 2003 Jul 15;102(2):749-55 [12663455.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3918-27 [14517188.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Haematologica. 2004 Oct;89(10):1275-6 [15477221.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3257-62 [7579423.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2677-84 [15591112.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2540-4 [16835383.001]
  • [Cites] Ann Hematol. 2007 Jun;86(6):435-42 [17256144.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2554-9 [17515573.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1067-74 [17640855.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2324-31 [17637813.001]
  • [Cites] Bone Marrow Transplant. 2007 Nov;40(10):973-8 [17873917.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):36-42 [18158959.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4004-13 [18239086.001]
  • [Cites] Ann Oncol. 2008 May;19(5):958-63 [18303032.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):741-7 [18541192.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5530-6 [18411419.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2687-93 [18625886.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):106-13 [19029417.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25 [19135950.001]
  • [Cites] Blood. 2009 Jan 29;113(5):995-1001 [18955565.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):511-8 [19075279.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1209-13 [19188674.001]
  • [Cites] Bone Marrow Transplant. 2009 Mar;43(6):509-11 [18955979.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4144-52 [19168784.001]
  • [Cites] Bone Marrow Transplant. 2009 May;43(9):701-8 [19029963.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • (PMID = 19737999.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207; United States / NCI NIH HHS / CA / T32 CA009207-35
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  • [Other-IDs] NLM/ NIHMS324593; NLM/ PMC3278670
  •  go-up   go-down


12. Pui CH, Thiel E: Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol; 2009 Aug;36(4 Suppl 2):S2-S16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hence, all protocols decrease or limit the use of cranial irradiation as central nervous system (CNS)-directed therapy, even in patients with high-risk presenting features, such as the presence of leukemia cells in the cerebrospinal fluid (even resulting from traumatic lumbar puncture), adverse genetic features, T-cell immunophenotype, and a large leukemia cell burden.
  • Options under investigation for the treatment of relapsed or refractory CNS leukemia in ALL patients include thiotepa and intrathecal liposomal cytarabine.
  • CNS involvement in non-Hodgkin lymphoma (NHL) is associated with young age, advanced stage, number of extranodal sites, elevated lactate dehydrogenase, and International Prognostic Index score.
  • Refractory CNS lymphoma in patients with NHL carries a poor prognosis, with a median survival of 2 to 6 months; the most promising treatment, autologous stem cell transplant, can extend median survival from 10 to 26 months.
  • CNS prophylaxis is required during the initial treatment of NHL subtypes that carry a high risk of CNS relapse, such as B-cell ALL, Burkitt lymphoma, and lymphoblastic lymphoma.
  • The use of CNS prophylaxis in the treatment of diffuse large B-cell lymphoma is controversial because of the low risk of CNS relapse ( approximately 5%) in this population.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Neurol. 1995 Sep;52(9):912-7 [7661730.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2091-7 [7662956.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):941-4 [8622043.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):543-8 [8630963.001]
  • [Cites] Acta Oncol. 1996;35(6):703-8 [8938217.001]
  • [Cites] Arch Neurol. 1997 Jul;54(7):854-9 [9236574.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2786-91 [9256120.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1178-84 [9454747.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):733-9 [9477107.001]
  • [Cites] Ann Oncol. 1998 Feb;9(2):191-4 [9553665.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):571-6 [10048430.001]
  • [Cites] Ann Hematol. 1999 Mar;78(3):145-9 [10211757.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Semin Neurol. 2004 Dec;24(4):395-404 [15637651.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):93-100 [15682069.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1791-8 [15858188.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Neurology. 2005 Aug 23;65(4):510-2 [16116106.001]
  • [Cites] Clin Transl Oncol. 2005 Jul;7(6):232-8 [16131445.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6489-98 [16170158.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):13-21 [16173958.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):193-200 [16197449.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3214-8 [17209054.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Apr;29(4):222-6 [17414563.001]
  • [Cites] Neurology. 2007 May 15;68(20):1674-9 [17502548.001]
  • [Cites] Pediatr Blood Cancer. 2007 Sep;49(3):250-5 [16856155.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1849-51 [17786723.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4813-20 [17947730.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • [Cites] Leuk Lymphoma. 2008 Aug;49(8):1427-30 [18766957.001]
  • [Cites] Leuk Lymphoma. 2008 Aug;49(8):1553-9 [18766969.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):390-6 [11839837.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):773-9 [11857312.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1033-4 [11937185.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 May;24(4):274-8 [11972095.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):587-93 [12002763.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1099-107 [12176790.001]
  • [Cites] JAMA. 2002 Oct 23-30;288(16):2001-7 [12387652.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):184-8 [12525508.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Dec;15(4):713-28 [12617872.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1798-809 [12721257.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):955-62 [12854893.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4284-9 [12920037.001]
  • [Cites] Oncology. 2005;69(3):256-60 [16166814.001]
  • [Cites] Ann Hematol. 2006 Jan;85(1):45-50 [16132909.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Pediatrics. 2006 Mar;117(3):876-81 [16510670.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(2):353-9 [16516133.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2332-6 [16710032.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2540-6 [16700036.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3142-9 [16809737.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1165-73 [16609069.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1339-48 [17046466.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):159-65 [16699873.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):319-32 [16884838.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2431-2 [17169783.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):149-57 [17018708.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2479-85 [10561312.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):335-43 [10830740.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(3A):352-8 [10905773.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):685-90 [10942056.001]
  • [Cites] Semin Oncol. 2000 Oct;27(5):540-59 [11049022.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3381-4 [11071631.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):157-63 [11161370.001]
  • [Cites] Leukemia. 2001 Feb;15(2):208-16 [11236936.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):129-33 [14679132.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):762-8 [15009064.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3916-21 [15459213.001]
  • [Cites] Am J Med. 1977 Aug;63(2):200-7 [888843.001]
  • [Cites] Cancer. 1982 Feb 1;49(3):586-95 [7059915.001]
  • [Cites] Scand J Haematol. 1985 Nov;35(5):487-96 [4089528.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • [Cites] Blood. 1988 Nov;72(5):1784-9 [3052630.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):736-41 [2491958.001]
  • [Cites] J Comput Assist Tomogr. 1990 Jul-Aug;14(4):536-41 [2370352.001]
  • [Cites] Hematol Oncol. 1990 May-Jun;8(3):141-5 [2373491.001]
  • [Cites] Am J Clin Oncol. 1991 Dec;14(6):478-82 [1720278.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1596-8 [8453629.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):314-9 [8321259.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1990-2001 [8410124.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2415-22 [7964958.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2594-600 [7989934.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):177-9 [7799017.001]
  • [Cites] Med Pediatr Oncol. 1995 Jul;25(1):22-7 [7752998.001]
  • (PMID = 19660680.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 107
  • [Other-IDs] NLM/ NIHMS162447; NLM/ PMC2805279
  •  go-up   go-down


13. Ballova V, Ladicka M, Vranovsky A, Lakota J: Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience. Neoplasma; 2008;55(5):428-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
  • With the aim to evaluate the long term outcome after high-dose chemotherapy and autologous stem cell transplantation (HDCT+ASCT) in patients with relapsed or refractory Hodgkin's lymphoma (HL) we performed a retrospective analysis of patients transplanted at our centre.
  • Between January 1993 and December 2005, 126 consecutive patients with relapsed or refractory HL in the age of 16 to 65 years underwent HDCT+ASCT at our centre and were enrolled in this retrospective analysis.
  • Our results confirm the efficacy of HDCT+ASCT in relapsed or refractory HL with acceptable toxicity.
  • [MeSH-major] Antigens, CD34 / therapeutic use. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation / methods. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Analysis. Transplantation Conditioning. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665754.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


14. Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A: Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol; 2005 Aug;84(8):517-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
  • Patients with primary progressive or refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) have a particularly poor prognosis.
  • Patients aged 18-55 years with primary progressive or refractory relapsed HD and aggressive NHL were included.
  • Patients received high-dose etoposide (2000 mg/m(2)) followed by peripheral blood stem cell harvest (PBSC).
  • Patients with bulky disease (>5 cm) or residual lymphoma received involved field radiotherapy.
  • Tandem HDCT followed by autologous stem cell transplantation (ASCT) offers a chance of cure in these poor prognostic patients, but is associated with risks.
  • [MeSH-major] Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759115.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Veres G, Baldassano RN, Mamula P: Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs; 2007;67(12):1703-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infliximab, the chimeric monoclonal IgG(1) antibody to tumour necrosis factor-alpha, is indicated for medically refractory luminal and fistulising paediatric Crohn's disease.
  • However, newly reported cases of hepatosplenic T-cell lymphoma in young patients with IBD treated with infliximab and mercaptopurine therapy raise concern, and long-term follow-up studies are necessary to determine the true malignancy risk.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 2004 Apr;43(4):527-9 [15024141.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Jul;39(1):46-52 [15187780.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3189-94 [11095340.001]
  • [Cites] J Pediatr. 2003 Oct;143(4):525-31 [14571234.001]
  • [Cites] J Intern Med. 2002 Dec;252(6):475-96 [12472908.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):2000-4 [12190167.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Apr;34(4):410-2 [11930099.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):531-3 [12688327.001]
  • [Cites] Ann Pharmacother. 2001 Jul-Aug;35(7-8):823-8 [11485127.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10 (1):36-40 [15058525.001]
  • [Cites] Am J Gastroenterol. 2003 Jan;98(1):104-11 [12526944.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):1148-57 [11040201.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Feb;17(3):387-93 [12562451.001]
  • [Cites] Gut. 2003 Jul;52(7):998-1002 [12801957.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):623-6 [11859881.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):917-24 [12671888.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Nov;35(5):708 [12454594.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2001 Sep;33 Suppl 1:S19-26 [11685971.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jul;10(4):417-20 [15475750.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63 [16441465.001]
  • [Cites] Drugs. 2005;65(16):2253-86 [16266194.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Jul;41(1):1-7 [15990620.001]
  • [Cites] Inflamm Bowel Dis. 2004 Nov;10(6):745-50 [15626892.001]
  • [Cites] Eur Cytokine Netw. 2000 Mar;11(1):27-38 [10705296.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1455-66 [8194690.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1167-71 [15489577.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7 [17255842.001]
  • [Cites] Arch Dis Child. 2003 Nov;88(11):995-1000 [14612366.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Apr;2(4):309-13 [15067625.001]
  • [Cites] N Engl J Med. 2003 Feb 13;348(7):601-8 [12584368.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):833-8 [12738464.001]
  • [Cites] Gut. 1993 Jul;34(7):939-43 [8344582.001]
  • [Cites] Inflamm Bowel Dis. 2001 May;7 Suppl 1:S17-22 [11380038.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):307-11 [11964959.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8 [15691299.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2001 Sep;33 Suppl 1:S40-3 [11685975.001]
  • [Cites] Gut. 2006 Feb;55(2):228-33 [16120759.001]
  • [Cites] Clin Exp Immunol. 2000 May;120(2):241-6 [10792371.001]
  • [Cites] JAMA. 2006 May 17;295(19):2275-85 [16705109.001]
  • [Cites] Korean J Gastroenterol. 2005 Oct;46(4):297-301 [16247274.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Oct 1;18(7):741-7 [14510748.001]
  • [Cites] Inflamm Bowel Dis. 2001 Feb;7(1):34-7 [11233658.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Sep;39(3):265-9 [15319627.001]
  • [Cites] Dig Liver Dis. 2004 May;36(5):342-7 [15191204.001]
  • [Cites] Eur J Pediatr. 2002 May;161(5):281-3 [12012225.001]
  • [Cites] Lancet. 2000 Nov 25;356(9244):1821-2 [11117919.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1029-35 [9321530.001]
  • [Cites] Scand J Gastroenterol. 2006 Sep;41(9):1064-72 [16938720.001]
  • [Cites] Gastroenterology. 2001 May;120(6):1330-8 [11313302.001]
  • [Cites] Drugs. 2004;64(16):1767-77 [15301561.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1315-24 [12818276.001]
  • [Cites] News Physiol Sci. 2001 Dec;16:272-7 [11719604.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):402-13 [14762776.001]
  • [Cites] Inflamm Bowel Dis. 2005 Mar;11(3):213-8 [15735427.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Feb;40(2):220-2 [15699701.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2462-76 [16339095.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Jan;40(1):67-9 [15625429.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Nov;2(11):602-10 [17075599.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):62-3 [15058530.001]
  • [Cites] Curr Rheumatol Rep. 2006 Aug;8(4):260-6 [16839504.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1962-74 [16762619.001]
  • [Cites] Clin Immunol. 2006 Jan;118(1):11-9 [16125467.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):32-9 [12851868.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):862-9 [15825070.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Apr;15(4):351-4 [12655253.001]
  • [Cites] Gut. 2004 Jan;53(1):70-7 [14684579.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):1140-5 [12671907.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2006 Mar;42(3):324-6 [16540804.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):761-9 [10500056.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Mar;44(3):312-7 [17325550.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):40-5 [16385252.001]
  • [Cites] J Pediatr. 2000 Aug;137(2):192-6 [10931411.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Apr;34(4):420-3 [11930102.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005112 [16856078.001]
  • [Cites] Gut. 2004 Sep;53(9):1366-73 [15306602.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Aug 15;18(4):425-31 [12940928.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1774-85 [12806611.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jan;17(1):75-84 [12492735.001]
  • [Cites] Arch Ophthalmol. 2005 Jul;123(7):903-12 [16009830.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1098-104 [11596589.001]
  • [Cites] Gut. 2004 Sep;53(9):1295-302 [15306588.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Apr;15(4):463-73 [11284774.001]
  • [Cites] J Immunol. 2006 Feb 15;176(4):2617-24 [16456024.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Mar;30(3):259-64 [10749408.001]
  • [Cites] Lancet. 2002 Apr 6;359(9313):1187-93 [11955536.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):332-9 [12591051.001]
  • [Cites] Drugs. 2006;66(11):1431-9 [16906776.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 May;38(5):502-8 [15097438.001]
  • [Cites] Ann Ital Med Int. 2005 Oct-Dec;20(4):211-7 [16610252.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1408-14 [12094858.001]
  • [Cites] Gut. 2006 Apr;55(4):505-9 [16188920.001]
  • [Cites] N Engl J Med. 1999 May 6;340(18):1398-405 [10228190.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jul 15;18(2):175-81 [12869077.001]
  • [Cites] N Engl J Med. 1994 Jun 30;330(26):1841-5 [8196726.001]
  • [Cites] Gut. 2002 Jul;51(1):37-43 [12077089.001]
  • [Cites] Colorectal Dis. 2006 May;8 Suppl 1:3-9 [16594957.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):819-26 [16143121.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976 [16843733.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2820-8 [12425554.001]
  • [Cites] Gut. 2003 Oct;52(10):1432-4 [12970135.001]
  • [Cites] J Clin Gastroenterol. 2003 May-Jun;36(5):411-3 [12702983.001]
  • [Cites] Skinmed. 2005 Nov-Dec;4(6):363-8 [16276152.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):895-902 [11040176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8093-8 [9223320.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Am J Gastroenterol. 2003 Aug;98(8):1821-6 [12907338.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):912-20 [15476155.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3469-77 [11151879.001]
  • [Cites] Inflamm Bowel Dis. 2004 Nov;10(6):723-30 [15626889.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):279-82 [17255846.001]
  • [Cites] Drugs. 2006;66(16):2059-65 [17112300.001]
  • [Cites] Lancet. 1993 Jul 17;342(8864):173-4 [8101267.001]
  • [Cites] Clin Immunol. 2005 Jun;115(3):250-9 [15893692.001]
  • [Cites] Clin Exp Ophthalmol. 2005 Oct;33(5):461-8 [16181269.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):298-301 [15076630.001]
  • [Cites] Dig Liver Dis. 2000 Dec;32(9):792-4 [11215560.001]
  • [Cites] Gastroenterology. 2004 May;126(6):1593-610 [15168370.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1805-11 [15940615.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 Aug;37(2):150-4 [12883301.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 May;34(5):558-60 [12050585.001]
  • [Cites] Dig Liver Dis. 2005 Dec;37(12):973-9 [16169305.001]
  • [Cites] J Clin Pathol. 1993 Aug;46(8):757-60 [8408704.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):572-9 [16327836.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 May;36(5):632-6 [12717087.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 15;23(8):1127-36 [16611273.001]
  • [Cites] Inflamm Bowel Dis. 2005 Nov;11 Suppl 1:S3-12 [16254481.001]
  • [Cites] Inflamm Bowel Dis. 2005 May;11(5):442-6 [15867583.001]
  • [Cites] Minerva Pediatr. 2006 Apr;58(2):139-57 [16835574.001]
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):876-85 [14985485.001]
  • [Cites] Ophthalmology. 2006 Feb;113(2):308-14 [16406545.001]
  • [Cites] Inflamm Bowel Dis. 2001 May;7(2):83-8 [11383595.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Jul;39(1):12-4 [15187774.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):621-30 [16678077.001]
  • [Cites] Inflamm Bowel Dis. 2003 Mar;9(2):98-103 [12769443.001]
  • (PMID = 17683171.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  • [Number-of-references] 139
  •  go-up   go-down


16. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC: In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol; 2010 Aug;161(2):290-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a Vgamma9Vdelta2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients.
  • However, a statistically significant correlation of clinical outcome with peripheral Vgamma9Vdelta2 T cell numbers emerged, as seven patients who failed to sustain Vgamma9Vdelta2 T cells showed progressive clinical deterioration, while three patients who sustained robust peripheral Vgamma9Vdelta2 cell populations showed declining CA15-3 levels and displayed one instance of partial remission and two of stable disease, respectively.
  • In the context of an earlier trial in prostate cancer, these data emphasize the strong linkage of Vgamma9Vdelta2 T cell status to reduced carcinoma progression, and suggest that zoledronate plus low-dose IL-2 offers a novel, safe and feasible approach to enhance this in a subset of treatment-refractory patients with advanced breast cancer.
  • [MeSH-major] Breast Neoplasms / therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Immunotherapy / methods. Interleukin-2 / therapeutic use. Receptors, Antigen, T-Cell, gamma-delta / metabolism. T-Lymphocyte Subsets / cytology
  • [MeSH-minor] Adjuvants, Immunologic / adverse effects. Adjuvants, Immunologic / pharmacology. Adjuvants, Immunologic / therapeutic use. Aged. Antigens, CD27 / metabolism. Antigens, CD45 / metabolism. Cell Proliferation / drug effects. Chemokines / blood. Cytokines / blood. Disease Progression. Esterases / metabolism. Female. Hemiterpenes / pharmacology. Humans. Interferon-gamma / metabolism. Lymphocyte Activation / drug effects. Lymphocyte Count. Lysine / analogs & derivatives. Lysine / metabolism. Middle Aged. Mucin-1 / blood. Organophosphorus Compounds / pharmacology. Remission Induction. Salvage Therapy. TNF-Related Apoptosis-Inducing Ligand / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Lysine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):31-8 [18458903.001]
  • [Cites] Bone. 2009 Dec;45(6):1153-60 [19699819.001]
  • [Cites] Cancer Invest. 2008 Dec;26(10):1024-31 [19093260.001]
  • [Cites] Br J Haematol. 2009 Jan;144(2):245-50 [19016713.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):679-91 [19213681.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2307-12 [19171897.001]
  • [Cites] J Immunother. 2009 Apr;32(3):310-21 [19242369.001]
  • [Cites] Exp Hematol. 2009 Aug;37(8):956-68 [19409955.001]
  • [Cites] Immunity. 2009 Aug 21;31(2):184-96 [19699170.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Springer Semin Immunopathol. 2000;22(3):191-217 [11116953.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Immunity. 2001 Jul;15(1):83-93 [11485740.001]
  • [Cites] Expert Rev Anticancer Ther. 2002 Apr;2(2):137-8 [12113230.001]
  • [Cites] Oncologist. 2002;7(6):481-91 [12490736.001]
  • [Cites] J Exp Med. 2003 Jan 20;197(2):163-8 [12538656.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6 Suppl 1):S10-8 [12562046.001]
  • [Cites] FEBS Lett. 2003 Jun 5;544(1-3):4-10 [12782281.001]
  • [Cites] Blood. 2003 Jul 1;102(1):200-6 [12623838.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2394-9 [12855610.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):391-7 [12900516.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):433-42 [12900519.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2310-1 [12959943.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Science. 1994 Apr 8;264(5156):267-70 [8146660.001]
  • [Cites] Nature. 1995 May 11;375(6527):155-8 [7753173.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):285-8 [15621815.001]
  • [Cites] Immunity. 2005 Jan;22(1):71-80 [15664160.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):397-405 [15864281.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4110-6 [15961759.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):383-93 [16622476.001]
  • [Cites] Adv Immunol. 2006;90:1-50 [16730260.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1630-7 [16646079.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):5-8 [17210676.001]
  • [Cites] Cancer Immunol Immunother. 2007 Apr;56(4):469-76 [16850345.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2078-85 [16973957.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4304-14 [17371987.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7450-7 [17671215.001]
  • [Cites] Immunity. 2007 Aug;27(2):334-48 [17656116.001]
  • [Cites] Clin Breast Cancer. 2007 Dec;7(11):833-40 [18269772.001]
  • [Cites] Cancer Immunol Immunother. 2008 Nov;57(11):1599-609 [18301889.001]
  • [Cites] Expert Opin Pharmacother. 2008 Oct;9(15):2639-60 [18803451.001]
  • [Cites] Nat Rev Immunol. 2009 Oct;9(10):704-16 [19859065.001]
  • [Cites] J Med Chem. 2008 Nov 13;51(21):6800-7 [18937434.001]
  • (PMID = 20491785.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 085780; United Kingdom / Cancer Research UK / / C28524/A9497; United Kingdom / Wellcome Trust / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, CD27; 0 / Chemokines; 0 / Cytokines; 0 / Diphosphonates; 0 / Hemiterpenes; 0 / Imidazoles; 0 / Interleukin-2; 0 / Mucin-1; 0 / N-benzyloxy-carbonyl-lysine thiobenzyl; 0 / Organophosphorus Compounds; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / T-cell receptor Vdelta2, human; 0 / T-cell receptor Vgamma9, human; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 358-71-4 / isopentenyl pyrophosphate; 6XC1PAD3KF / zoledronic acid; 82115-62-6 / Interferon-gamma; EC 3.1.- / Esterases; EC 3.1.3.48 / Antigens, CD45; K3Z4F929H6 / Lysine
  • [Other-IDs] NLM/ PMC2909411
  •  go-up   go-down


17. Sugimoto T, Matano S, Nishijima H, Kakuta K, Inamura K, Okamura T, Munemoto S, Satoh S: [Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases]. Gan To Kagaku Ryoho; 2007 Jan;34(1):125-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
  • Localized refractory diffuse large B-cell lymphomas (DLBCL) were treated with concurrent chemo-radiotherapy.
  • Lymphoma enlarged even after the fourth courses of chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP).
  • A lymphoma enlarged after eighth courses of CHOP.
  • Both cases achieved complete remission after the combined therapy, however, lymphoma in one case recurred three months after the therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220687.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MMIP protocol
  •  go-up   go-down


18. Cheson BD, Rummel MJ: Bendamustine: rebirth of an old drug. J Clin Oncol; 2009 Mar 20;27(9):1492-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bendamustine is a unique cytotoxic agent with structural similarities to alkylating agents and antimetabolites, but which is non-cross-resistant with alkylating agents and other drugs in vitro and in the clinic.
  • Early clinical studies conducted in the German Democratic Republic more than 30 years ago suggested promising activity in indolent non-Hodgkin's lymphoma (NHL).
  • Two North American trials reported responses in more than 70% of patients with chemotherapy- and rituximab-refractory disease, suggesting that bendamustine may be the most effective drug available for this patient population.
  • Response rates of 90% to 92%, with complete remission in 55% to 60%, have been reported in patients with follicular and mantle-cell lymphoma with the combination of bendamustine and rituximab.
  • Activity has also been noted in patients with breast cancer and small-cell lung cancer [corrected].

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Jun 10;27(17):2892
  • (PMID = 19224851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  • [Number-of-references] 66
  •  go-up   go-down


19. Schnaiter A, Stilgenbauer S: Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget; 2010 Nov;1(7):472-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory chronic lymphocytic leukemia--new therapeutic strategies.
  • Importantly, the monoclonal CD20 antibody ofatumumab has now shown efficacy in F and A double-refractory CLL.
  • Further B-cell antigens are targeted by lumiliximab (CD23), TRU-016 (CD37) and blinatumomab (CD19).
  • Apart from monoclonal antibody therapies, a great number of small molecules are examined for the treatment of refractory and relapsed CLL.
  • Typical targets are regulators of the cell cycle and antiapoptotic molecules like the members of the Bcl-2 family.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Therapies, Investigational / methods

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):6012-8 [19826119.001]
  • [Cites] Blood. 2000 Jul 15;96(2):393-7 [10887097.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3994-4001 [19597025.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1711-20 [12655528.001]
  • [Cites] Leuk Lymphoma. 2010 Jan;51(1):85-8 [20055660.001]
  • [Cites] Blood. 2010 Jan 21;115(3):489-95 [19843887.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1749-55 [20194866.001]
  • [Cites] Cancer. 2010 May 15;116(10):2360-5 [20225334.001]
  • [Cites] Lancet. 2010 Oct 2;376(9747):1164-74 [20888994.001]
  • [Cites] J Clin Oncol. 2010 Oct 10;28(29):4473-9 [20697090.001]
  • [Cites] Blood. 2011 Apr 28;117(17):4519-29 [21378274.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1165-71 [9694704.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3804-16 [9808574.001]
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4176-81 [15930354.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] Leuk Res. 2005 Nov;29(11):1253-7 [15916806.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7024-31 [16145065.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7697-702 [16186597.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Exp Hematol. 2006 Dec;34(12):1663-9 [17157163.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55 [17671129.001]
  • [Cites] Exp Hematol. 2007 Oct;35(10):1527-37 [17697742.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3421-8 [18451170.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] Blood. 2008 Aug 15;112(4):975-80 [18411418.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1443-52 [18550857.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):170-6 [18510700.001]
  • [Cites] Br J Haematol. 2008 Dec;143(5):698-706 [19062342.001]
  • [Cites] Blood. 2009 Jan 1;113(1):149-53 [18836097.001]
  • [Cites] Blood. 2009 Jan 8;113(2):299-305 [18931344.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4403-13 [19008458.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [CommentIn] Oncotarget. 2011 Oct;2(10):737-8 [22006556.001]
  • (PMID = 21317446.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC3248129
  •  go-up   go-down


20. Sandrini S, Valerio F, Insalaco M: [Kidney transplantation and lymphomas]. G Ital Nefrol; 2010 Sep-Oct;27 Suppl 50:S46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse large B-cell lymphoma is the most frequent form of PTLD.
  • Chemotherapy becomes essential in relapsed or refractory disease, but it significantly increases the risk of life-threatening infections.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922695.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Hori T, Suzuki N, Mizue N, Hatakeyama N, Takamuro M, Tsutsumi H: Relapse of T-cell all after stem cell transplant presenting as hypertrophic cardiomyopathy: the value of non-invasive diagnostic imaging in detecting cardiac leukemia. Pediatr Blood Cancer; 2006 Jan;46(1):108-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of T-cell all after stem cell transplant presenting as hypertrophic cardiomyopathy: the value of non-invasive diagnostic imaging in detecting cardiac leukemia.
  • We describe a 14-year-old female with acute lymphoblastic leukemia (ALL) with a mediastinal mass at diagnosis who developed hypertrophic cardiomyopathy (HC) after stem cell transplantation (SCT).
  • During refractory relapse after SCT using bone marrow from her HLA-matched sibling, she underwent whole thorax irradiation because of pleural effusion and a recurrent mediastinal mass.
  • However, isolated cardiac relapse was finally diagnosed by several non-invasive imaging techniques.
  • [MeSH-major] Cardiomyopathy, Hypertrophic / etiology. Diagnostic Imaging. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Myocardium / pathology
  • [MeSH-minor] Adolescent. Female. Humans. Magnetic Resonance Imaging. Recurrence. Stem Cell Transplantation. Tomography, X-Ray Computed


22. Zane C, Venturini M, Sala R, Calzavara-Pinton P: Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed; 2006 Oct;22(5):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma.
  • BACKGROUND: Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL).
  • If lesions are refractory to topical steroids, therapies such as localized chemotherapy, photochemotherapy and radiotherapy are available.
  • However, they have several acute and chronic side-effects and toxicity may accumulate if repeated and protracted treatment cycles are delivered to refractory or relapsing lesions.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948827.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 22
  •  go-up   go-down


23. O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J: Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol; 2009 Apr;145(1):34-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
  • The recent approval of bortezomib for the treatment of mantle cell lymphoma (MCL) by the US Food and Drug Administration is based on the results of the multicentre PINNACLE study with supportive data from a number of single and multicentre Phase 2 studies.
  • The ORR in relapsed and refractory patients was 50% and 43% respectively (P = 0.74), while both populations of patients exhibited essentially similar progression-free survival (PFS; 5.6 months vs. 3.9 months, P = 0.81).
  • The data showed similar responses in relapsed and refractory patients as well as remission durations similar to prior therapy, suggesting that there may be little cross-resistance with other conventional cytotoxic agents.
  • Importantly, these data suggest that MCL patients with refractory or poorly responsive disease may still derive meaningful clinical benefit from treatment with bortezomib.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Boronic Acids / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Protease Inhibitors / administration & dosage. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220284.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / U01 CA 69913
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


24. Saito T, Usui N, Asai O, Dobashi N, Ida H, Kawakami M, Yano S, Osawa H, Takei Y, Takahara S, Ogasawara Y, Yamaguchi Y, Minami J, Aiba K: Pseudo-Gaucher cell proliferation associated with myelodysplastic syndrome. Int J Hematol; 2007 May;85(4):350-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Gaucher cell proliferation associated with myelodysplastic syndrome.
  • We report an extremely rare case of pseudo-Gaucher cell proliferation with myelodysplastic syndrome (MDS).
  • A diagnosis of MDS, subclassified as refractory anemia, was then made according to World Health Organization classification guidelines.
  • Pseudo-Gaucher cell proliferation and infiltration might therefore be observed in other patients presenting with MDS.
  • [MeSH-major] Cell Proliferation. Gaucher Disease / pathology. Gaucher Disease / physiopathology. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / physiopathology


25. Muram-Zborovski T, Loeb D, Sun T: Primary intestinal intraepithelial natural killer-like T-cell lymphoma: case report of a distinct clinicopathologic entity. Arch Pathol Lab Med; 2009 Jan;133(1):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intestinal intraepithelial natural killer-like T-cell lymphoma: case report of a distinct clinicopathologic entity.
  • Intestinal T-cell lymphoma is a heterogenous group.
  • These tumors differ in their association with enteropathy, intraepithelial or nonintraepithelial origin, primary or secondary involvement, and T-cell or natural killer-like T-cell immunophenotype.
  • There are also nonneoplastic conditions, such as celiac disease, refractory sprue, and reactive T-cell infiltration that mimic intestinal T-cell lymphoma.
  • A subset of primary intestinal intraepithelial T-cell lymphoma has emerged in recent years that is distinguished from enteropathy-type T-cell lymphoma in terms of clinical presentation (nonenteropathic), morphology (monomorphic small to medium-sized cells), immunophenotype (CD3(-)CD8(+)CD56(+)), and cytogenetics.
  • We report such a case with a unique immunophenotype (CD3(-), cytoplasmic CD3(+), CD4(-), CD8(+), CD5(-), CD7(+), CD16(-), CD56(+), CD57(-), CD103(+), T-cell intracellular antigen 1(+), and betaF1(+)) that is comparable to that of a newly identified subset of intraepithelial T cells.
  • We recommend a large monoclonal antibody panel for the differential diagnosis of this heterogeneous group of T-cell lymphoma.
  • [MeSH-major] Intestinal Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123726.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Qian J, Xue Y, Pan J, Cen J, Wang W, Chen Z: Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura. Int J Hematol; 2005 Feb;81(2):142-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura.
  • Refractory thrombocytopenia (RTC) is an unusual subtype of myelodysplastic syndrome (MDS) that initially presents as chronic pure thrombocytopenia.
  • We describe the case of a patient with RTC and trisomy 8 for whom a bone marrow mononuclear cell (BMNC) gene expression profile was obtained by means of a complementary DNA microarray analysis.


27. Ishitsuka K, Suzumiya J, Aoki M, Ogata K, Hara S, Tamura K: Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica; 2007 May;92(5):719-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
  • Arsenic trioxide (As2O3) with or without interferon-a (IFN) was given to 4 patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATLL).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. Interferon-alpha / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Oxides / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor / drug effects. Disease Progression. Female. Humans. Male. Recurrence. Thrombocytopenia / drug therapy. Thrombocytopenia / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488707.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Interferon-alpha; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


28. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW: Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol; 2005 Oct;131(2):223-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
  • Forty-four patients with relapsed or refractory aggressive histology non-Hodgkin lymphoma (NHL) (diffuse large B cell, n = 23; peripheral T cell, n = 5; transformed B cell, n = 16) proceeded to allogeneic stem cell transplant (allo-SCT) between 1987 and 2003.
  • Lymphoma relapse <12 months after initial therapy predicted for increased risk of relapse post-transplant (P = 0.02).
  • Patients with chemorefractory lymphoma were not at increased risk of relapse (P = 0.20) with four of nine patients remaining alive without disease 12-103 months post-transplant.
  • In conclusion, allo-SCT for relapsed or refractory aggressive histology NHL results in long-term EFS and OS of 40-50%.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / surgery


29. Harousseau JL: Ten years of improvement in the management of multiple myeloma: 2000-2010. Clin Lymphoma Myeloma Leuk; 2010 Dec;10(6):424-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2000, the most important therapeutic improvement in multiple myeloma (MM) had been the introduction of high-dose therapy (HDT) supported by autologous stem cell transplantation, but this strategy was proposed only to younger patients without comorbidities.
  • These three agents, two immunomodulatory agents (IMIDs; thalidomide and lenalidomide) and one proteasome inhibitor (bortezomib) have been initially used in relapsed or refractory patients and rapidly added to frontline therapy both in younger and older patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Multiple Myeloma / therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21156460.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  •  go-up   go-down


30. Wang D, Long J, Dai F, Liang M, Feng XH, Lin X: BCL6 represses Smad signaling in transforming growth factor-beta resistance. Cancer Res; 2008 Feb 1;68(3):783-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In accordance, B-cell lymphoma cells with a high expression level of BCL6 were found to be refractory to TGF-beta antiproliferative response, whereas knockdown of BCL6 expression in B-cell lymphoma cells partially restores the TGF-beta responses.
  • This study provides strong evidence that overexpression of BCL6 contributes to TGF-beta resistance in B-cell lymphoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245479.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM063773-04S1; United States / NIDDK NIH HHS / DK / R01DK073932; United States / NIGMS NIH HHS / GM / R01 GM063773-04; United States / NIAMS NIH HHS / AR / R01 AR053591; United States / NIGMS NIH HHS / GM / R01GM63773; United States / NCI NIH HHS / CA / R01 CA108454-04; United States / NIDDK NIH HHS / DK / P50DK064233; United States / NIGMS NIH HHS / GM / R01 GM063773; United States / NCI NIH HHS / CA / R21CA11293; United States / NCI NIH HHS / CA / R01 CA108454; United States / NCI NIH HHS / CA / R01CA108454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Chromatin; 0 / DNA-Binding Proteins; 0 / RNA, Small Interfering; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; EC 2.3.1.48 / E1A-Associated p300 Protein; EC 2.3.1.48 / EP300 protein, human
  •  go-up   go-down


36. Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG, Huber C: Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma. Ann Hematol; 2006 Nov;85(11):769-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
  • To better define the role of rituximab in salvage and high-dose therapy (HDT) for relapsed or refractory non-Hodgkin's lymphoma (NHL), patients treated before the implementation of rituximab in salvage and HDT (n = 57, control group) were compared with patients with rituximab included in this procedure (n = 36, study group).
  • Despite the absence of differences in stem cell collection, haematopoietic recovery was delayed in patients with aggressive NHL treated in the study group: median days to absolute neutrophil count more than 0.5 x 10(9)/l, 11 vs 10 (p = 0.01), and platelets more than 20 x 10(9)/l, 14 vs 11 (p = 0.0005), with an increased requirement for platelet transfusions.
  • No similar observations were made in indolent lymphoma patients.
  • For patients with indolent lymphoma, no comparable benefit was detectable.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Lymphoma, B-Cell / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Hematopoiesis. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Remission Induction. Rituximab. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896912.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


37. Swords R: Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords. Drugs; 2007;67(17):2655-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Philadelphia Chromosome. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Humans. Imatinib Mesylate. Prognosis. Recurrence. Stem Cell Transplantation. Survival Rate. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034599.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


38. Olejniczak SH, Blickwedehl J, Belicha-Villanueva A, Bangia N, Riaz W, Mavis C, Clements JL, Gibbs J, Hernandez-Ilizaliturri FJ, Czuczman MS: Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood; 2010 Dec 16;116(25):5605-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we used a model of therapy-resistant B-cell non Hodgkin lymphoma (B-NHL) developed in our laboratory along with primary B-NHL cells to study basic mechanisms of bortezomib activity.
  • Our data demonstrate that bortezomib is capable of killing B-NHL cells via multiple mechanisms, regardless of their basal apoptotic potential, and contributes to growing evidence that proteasome inhibitors can act via modulation of B-cell lymphoma 2 (Bcl-2) family proteins.
  • The capacity of bortezomib to act independently of the intrinsic apoptotic threshold of a given B-NHL cell suggests that bortezomib-based therapies could potentially overcome resistance and result in relevant clinical activity in a relapsed/refractory setting.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):88-96 [10561023.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Dec;327(3):645-56 [18776064.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]
  • [Cites] Oncologist. 2003;8(6):508-13 [14657528.001]
  • [Cites] Nat Cell Biol. 2004 May;6(5):443-50 [15077116.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3207-15 [15131062.001]
  • [Cites] Br J Haematol. 2004 Jun;125(5):655-65 [15147382.001]
  • [Cites] Cancer Invest. 2004;22(2):304-11 [15199612.001]
  • [Cites] Curr Opin Cell Biol. 2004 Dec;16(6):663-9 [15530778.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4711-6 [15483015.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):694-704 [15681517.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):393-403 [15694340.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6282-93 [16024630.001]
  • [Cites] Oncogene. 2005 Jul 21;24(31):4993-9 [15824729.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5847-55 [16115925.001]
  • [Cites] Blood. 2006 Jan 1;107(1):257-64 [16166592.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):11923-32 [16446371.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2105-12 [16606971.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4907-16 [16507771.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1270-81 [17283164.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1783-92 [17308121.001]
  • [Cites] Blood. 2007 May 15;109(10):4441-9 [17227835.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5418-24 [17545623.001]
  • [Cites] Nature. 2007 Jun 14;447(7146):859-63 [17568747.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4 [17875757.001]
  • [Cites] Oncogene. 2008 Feb 21;27(9):1189-97 [17828309.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1550-60 [18316580.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1561-70 [18316581.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):613-26 [18687642.001]
  • [Cites] Leuk Lymphoma. 2008;49 Suppl 1:59-66 [18821434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16165-70 [18845680.001]
  • [Cites] Oncogene. 2008 Oct 27;27(50):6452-61 [18955972.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • (PMID = 20930068.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA103985; United States / NCI NIH HHS / CA / R01 CA136907; United States / NCI NIH HHS / CA / CA103985-1; United States / NCI NIH HHS / CA / CA136907-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC3031407
  •  go-up   go-down


39. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene; 2005 Mar 24;24(13):2121-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
  • The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has significantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL).
  • The exact in vivo mechanisms of action of rituximab are not fully understood, although antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis have been suggested.
  • The B-cell restricted cell surface phosphoprotein CD20 is involved in many cellular signaling events including proliferation, activation, differentiation, and apoptosis upon crosslinking.
  • ARL (acquired immunodeficiency syndrome (AIDS)-related lymphoma) and non-ARL cell lines have been examined as in vitro model systems.
  • Rituximab upregulates Raf-1 kinase inhibitor protein (RKIP) expression in non-ARL cells.
  • Studies presented herein also reveal several intracellular targets modified by rituximab, which can be exploited for therapeutic and prognostic purposes in the treatment of patients with rituximab- and drug-refractory NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Antigens, CD / drug effects. Antigens, CD20 / drug effects. Antigens, CD20 / genetics. Antigens, CD20 / physiology. Cell Survival / drug effects. Cloning, Molecular. Humans. Mice. Recombinant Fusion Proteins / therapeutic use. Rituximab


40. Yang ZZ, Chen XH, Wang D: Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector. Clin Lymphoma Myeloma; 2007 Jan;7(4):296-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a means to overcome MM tumor cell resistance and/or sensitize tumor cells to chemotherapeutic treatments currently used, we examined the role of human apurinic/apyrimidinic endonuclease 1 (APE1) in resistance and prognosis in patients with MM.
  • Positive rate of APE1 expression beyond grade 2 in the relapsed/refractory group was significantly higher than that in the untreated group.
  • Because APE1 was overexpressed in refractory/relapsed MM cells, siRNA-targeted technology was used to decrease APE1 levels in KM3 cells, with protein levels deceasing to 80%-90% within 24 hours and continuing to decease for 72 hours.
  • A decrease in APE1 levels in siRNA-treated KM3 cells led to enhanced cell sensitization to melphalan.
  • CONCLUSION: The findings herein present prognostic and therapeutic implications for treating relapsed/refractory MM.
  • [MeSH-minor] Antigens, CD38 / genetics. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Feasibility Studies. Female. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Male. Microscopy, Confocal. Middle Aged. Prognosis. RNA, Small Interfering / pharmacology. Sensitivity and Specificity. Time Factors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324338.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.2.2.5 / Antigens, CD38; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; Q41OR9510P / Melphalan
  •  go-up   go-down


41. Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS: Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol; 2009 Aug;146(3):282-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
  • Toll-like receptor-9 (TLR-9) agonists have pleotropic effects on both the innate and adaptive immune systems, including increased antigen expression, enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and T helper cell type 1 shift in the immune response.
  • We combined a TLR-9 agonist (1018 ISS, 0.2 mg/kg sc weekly x 4 beginning day 8) with standard rituximab (375 mg/m(2) weekly x 4) in patients (n = 23) with relapsed/refractory, histologically confirmed follicular lymphoma, and evaluated immunological changes following the combination.
  • This study is the first to histologically confirm perturbation of the local immune microenvironment following systemic biological therapy of follicular lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Toll-Like Receptor 9 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 2006 Sep-Oct;29(5):558-68 [16971811.001]
  • [Cites] Curr Treat Options Oncol. 2006 Jul;7(4):276-84 [16916488.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5350-7 [17135637.001]
  • [Cites] Int Immunopharmacol. 2006 Dec 20;6(13-14):2057-68 [17161362.001]
  • [Cites] Clin Immunol. 2007 Feb;122(2):139-45 [17008130.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97 [17255259.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2008-13 [17068155.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2493-500 [17675511.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6168-74 [17947483.001]
  • [Cites] Exp Hematol. 2008 Jan;36(1):69-77 [17959301.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):161-7 [18176597.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):71-4 [18381100.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):85-9 [18381102.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):902-9 [18464109.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2725-31 [18427151.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3979-86 [18711188.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2644-52 [10914705.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5626-34 [18765557.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Blood. 2002 Jan 1;99(1):67-74 [11756154.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):828-34 [12060117.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2253-64 [15073100.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5297-8 [15328164.001]
  • [Cites] Annu Rev Immunol. 1989;7:145-73 [2523712.001]
  • [Cites] J Cell Biochem. 1991 Apr;45(4):381-90 [1675219.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1059-70 [9276722.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Blood. 2005 Jan 15;105(2):489-95 [15358617.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1490-9 [15746051.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1675-82 [16030029.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]
  • [Cites] Cell. 2006 Feb 24;124(4):783-801 [16497588.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2957-64 [16825494.001]
  • (PMID = 19519691.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 024160; United States / NCI NIH HHS / CA / K23 CA102216; United States / PHS HHS / / A1054953; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NCI NIH HHS / CA / R21 CA103244; United States / NHLBI NIH HHS / HL / HL-007152; United States / NCI NIH HHS / CA / CA-102216; United States / NCI NIH HHS / CA / CA-103244; United States / NCRR NIH HHS / RR / UL1 RR024160; United States / NCI NIH HHS / CA / K23 CA102216-05; United States / NIAID NIH HHS / AI / R24 AI054953
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1018 oligonucleotide; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Chemokine CCL2; 0 / Chemokine CXCL10; 0 / IFIT2 protein, human; 0 / Oligodeoxyribonucleotides; 0 / Proteins; 0 / Toll-Like Receptor 9; 4F4X42SYQ6 / Rituximab; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS139957; NLM/ PMC2747261
  •  go-up   go-down


42. Richardson PG, Schlossman R, Mitsiades C, Hideshima T, Munshi N, Anderson K: Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma; 2005 Sep;6(2):84-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consolidation with high-dose therapy followed by single or double autologous stem cell transplantation has improved response and survival of patients with multiple myeloma (MM), but the disease remains incurable.
  • Bortezomib, a selective inhibitor of the proteasome, has proven to be safe and effective in patients with relapsed and/or refractory MM as monotherapy in phase II/III clinical trials and has produced promising activity in combination regimens with cytotoxic agents.
  • High complete and near-complete response rates after 2-4 cycles of bortezomib-based induction therapy may improve outcome in autologous stem cell transplantation recipients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Multiple Myeloma / therapy. Proteasome Inhibitors. Pyrazines / therapeutic use. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231845.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / beta 2-Microglobulin; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 49
  •  go-up   go-down


43. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A: Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol; 2009 Nov 1;27(31):5213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
  • PURPOSE: This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL).
  • PATIENTS AND METHODS: Patients with relapsed or refractory MCL were eligible for the study if they had adequate major organ function and performance status.
  • Those with CNS disease, pleural effusion, circulating lymphoma cells > or = 5,000/microL, or history of stem-cell transplant were ineligible.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy


44. Chandesris MO, Malamut G, Verkarre V, Meresse B, Macintyre E, Delarue R, Rubio MT, Suarez F, Deau-Fischer B, Cerf-Bensussan N, Brousse N, Cellier C, Hermine O: Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives. Gastroenterol Clin Biol; 2010 Nov;34(11):590-605
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives.
  • INTRODUCTION: Enteropathy-associated T-cell lymphoma (EATL) is a rare complication of celiac disease (<1% of lymphomas) and has a poor prognosis.
  • Refractory celiac disease (RCD), equivalent to low-grade intraepithelial T-cell lymphoma, could be an intermediary between celiac disease and high-grade invasive T-cell lymphoma.
  • [MeSH-major] Celiac Disease. Lymphoma, T-Cell


45. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant; 2005 Sep;11(9):688-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
  • To achieve long-term disease-free survival, high-dose therapy and autologous stem cell transplantation (ASCT) is the current standard approach in patients with relapsed or refractory Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL).
  • In this phase II study, 49 patients with relapsed or refractory HD (n = 22) and NHL (n = 27) with a median age of 42 years were treated with an IIVP salvage regimen consisting of ifosfamide, idarubicin, and etoposide.
  • Twenty-seven percent of the patients had primary refractory disease, whereas 22% and 51% had early and late relapses, respectively.
  • The IIVP regimen is a highly effective salvage regimen for patients with relapsed or refractory HD or NHL who are candidates for ASCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Salvage Therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125639.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; ZRP63D75JW / Idarubicin
  •  go-up   go-down


46. Haas A, Lobeck H, Hummel M, Maschmeyer G: [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma]. Dtsch Med Wochenschr; 2006 Oct 27;131(43):2386-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma].
  • [Transliterated title] Anhaltende Remission nach Immuntherapie bei zuvor refraktärem peripherem T-Non-Hodgkin-Lymphom.
  • INVESTIGATIONS: Histology revealed a peripheral T cell non-Hodgkin lymphoma (NHL).
  • Because response to treatment was only minimal a biopsy was performed which showed persisting malignant lymphoma.
  • CONCLUSION: In T-NHL with primary non-response it is especially difficult to induce a stable remission.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Immunotherapy. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054053.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A189DH42V / alemtuzumab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 1.1.1.27 / L-Lactate Dehydrogenase; CHOEP protocol
  •  go-up   go-down


47. Imataki O, Aoyama T, Tamai Y, Kawakami K: [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1633-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
  • Chemotherapy-susceptive multiple myeloma (MM) has an indication for high-dose melphalan (HDM) followed by autologous stem cell transplantation (auto-SCT).
  • In order to assess the potential of auto-SCT by HDM in a outpatient setting, we evaluated the toxicities of HDM compared with the ICE regimen generally applied to patients with refractory or relapsed lymphoma.
  • Gastrointestinal (GI) adverse events for a patient per hospital day were 0.93 for myeloma and 0.95 for lymphoma (no significant differences), with GI toxicity of more than grade 3, 0.08 and 0.12, respectively (p=0.07).
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Melphalan / administration & dosage. Multiple Myeloma / drug therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940379.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


48. Testa U, Riccioni R, Biffoni M, Diverio D, Lo-Coco F, Foà R, Peschle C, Frankel AE: Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood; 2005 Oct 1;106(7):2527-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On a molar basis, DT388IL-3[K116W] was significantly more active than DT388IL-3 in mediating leukemic cell killing.
  • The rate of cell killing induced by the 2 DT/IL-3 fusion proteins was significantly correlated with the level of IL-3Ralpha/IL-3Rbeta expressed on leukemic blasts.
  • These observations support a potential use of DT388IL-3[K116W] in the treatment of refractory AMLs and provide a simple biochemical parameter for the selection of eligible patients.

  • Genetic Alliance. consumer health - Diphtheria.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Apr;14(4):576-85 [10764142.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1004-13 [12006512.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2980-8 [12351411.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Cancer Immunol Immunother. 2005 Aug;54(8):799-806 [15614527.001]
  • [Cites] Protein Expr Purif. 2004 Jan;33(1):123-33 [14680969.001]
  • [Cites] Leukemia. 2004 Feb;18(2):219-26 [14671644.001]
  • [Cites] Exp Hematol. 2004 Mar;32(3):277-81 [15003313.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1647-56 [15370220.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Jul 15;158(2):152-60 [10406930.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1681-9 [15634662.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • (PMID = 15928038.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA76 178; United States / NCI NIH HHS / CA / R01CA90 263
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Growth Substances; 0 / Interleukin-3; 0 / Receptors, Interleukin-3; 0 / Recombinant Fusion Proteins
  • [Other-IDs] NLM/ PMC1895267
  •  go-up   go-down


49. Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson K: Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid; 2009;4:215-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To evaluate the evidence for the use of lenalidomide in its current indication in relapsed or refractory MM, and additionally its investigational use for the treatment of newly diagnosed MM.
  • EVIDENCE REVIEW: In patients with relapsed and refractory MM, adding lenalidomide to high-dose dexamethasone significantly improves response rates and time-to-progression, relative to high-dose dexamethasone alone.
  • Outcome is independent of patient age, number of previous therapies, type of previous therapy (including thalidomide or autologous stem cell transplantation), renal impairment, and beta(2)-microglobulin level.
  • ROLE IN THERAPY: The encouraging results obtained with lenalidomide alone and in combination with dexamethasone in patients with relapsed or refractory MM have led to its adoption as a recommended therapy in patients who have received at least one prior treatment.
  • Emerging evidence supports the ongoing investigation of lenalidomide in combination with low-dose dexamethasone, and in other combinations including bortezomib, for use both in relapsed, refractory, and newly diagnosed MM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):585-98 [17646864.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3892-901 [17679727.001]
  • [Cites] Br J Haematol. 2007 Sep;138(5):640-3 [17686058.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3557-60 [17690257.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4459-65 [17785703.001]
  • [Cites] Mayo Clin Proc. 2007 Oct;82(10):1179-84 [17908524.001]
  • [Cites] Leukemia. 2008 Feb;22(2):231-9 [17972944.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1101-9 [17989313.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Oct;5(10 Suppl 15):7-19, quiz 21-2 [18000495.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:317-23 [18024646.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2123-32 [18032762.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2133-42 [18032763.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4250-6 [7492784.001]
  • [Cites] Eur J Haematol. 1993 Feb;50(2):95-102 [8440364.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1101-7 [8624271.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2659-66 [9215838.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):380-6 [10384139.001]
  • [Cites] Br J Haematol. 1999 Sep;106(4):1005-12 [10520004.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1295-314, xi [10626152.001]
  • [Cites] Mayo Clin Proc. 2000 Sep;75(9):897-901 [10994824.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2943-50 [11049970.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):763-70 [15953002.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1969-76 [16079895.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 5):S24-30 [16085014.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4050-3 [16118317.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):759-66 [16221046.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8 [16344099.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2183-6 [18032768.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Leukemia. 2008 Apr;22(4):673-5 [18414492.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8 [18541199.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] Blood. 2009 Jul 23;114(4):772-8 [19471019.001]
  • [Cites] Cancer. 1975 Sep;36(3):842-54 [1182674.001]
  • [Cites] Ann Hematol. 2005 Sep;84(9):594-600 [15744524.001]
  • [Cites] Leuk Res. 2005 May;29(5):587-90 [15755512.001]
  • [Cites] Microvasc Res. 2005 Jan;69(1-2):56-63 [15797261.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Curr Treat Options Oncol. 2005 May;6(3):241-53 [15869735.001]
  • [Cites] Clin Lymphoma Myeloma. 2005 Nov;6(3):181-90 [16354323.001]
  • [Cites] Br J Haematol. 2006 Feb;132(4):410-51 [16412016.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1013-20 [16614247.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(11):1612-22 [16750621.001]
  • [Cites] Blood. 2006 Jul 1;108(1):405-6; author reply 406 [16790588.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3289-94 [16873668.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3556-9 [16873673.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Jul;7(1):33-41 [16879768.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1566-71 [11238092.001]
  • [Cites] Blood. 2001 Jul 1;98(1):210-6 [11418482.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1614-5 [11520815.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):991-5 [11521808.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):175-87 [11990854.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4569-75 [12576322.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):293-304 [12732167.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):32-5 [12837152.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2732-9 [12860952.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):314-22 [15057291.001]
  • [Cites] Curr Cancer Drug Targets. 2004 May;4(3):235-56 [15134532.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):430-42 [15231250.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(6):485-90 [15286691.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1149-50 [16885059.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1766-71 [16980599.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:338-47 [17124081.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2767-72 [17148584.001]
  • [Cites] Ann Hematol. 2007 Mar;86(3):159-72 [17205287.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):746-55 [17234786.001]
  • [Cites] Expert Opin Pharmacother. 2007 Mar;8(4):497-509 [17309344.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):46-55 [17325847.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1150-7 [17344913.001]
  • [Cites] Blood. 2007 Jul 1;110(1):74-81 [17371947.001]
  • [Cites] Br J Haematol. 2007 May;137(3):268-9 [17408469.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):458-68 [17454585.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Apr;7 Suppl 4:S139-44 [17562251.001]
  • [Cites] Leukemia. 2007 Sep;21(9):2035-42 [17581613.001]
  • [Cites] Oncologist. 2007 Jun;12(6):664-89 [17602058.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):93-9 [17608711.001]
  • (PMID = 20694078.001).
  • [ISSN] 1555-175X
  • [Journal-full-title] Core evidence
  • [ISO-abbreviation] Core Evid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2899783
  • [Keywords] NOTNLM ; evidence / lenalidomide / multiple myeloma / outcomes / treatment
  •  go-up   go-down


50. Bhat SA, Czuczman MS: Novel antibodies in the treatment of non-Hodgkin's lymphoma. Neth J Med; 2009 Sep;67(8):311-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel antibodies in the treatment of non-Hodgkin's lymphoma.
  • Monoclonal antibodies (mAbs) have revolutionised the treatment of malignancies, especially non-Hodgkin's lymphoma (NHL).
  • Rituximab, a monoclonal antibody directed against CD20 on B cells, was the first monoclonal antibody to be approved by the US Food and Drug Association (FDA) in 1997 for the treatment of patients with relapsed/refractory, follicular or low-grade NHL .
  • However, it was soon realised that not all patients respond to rituximab therapy and close to 60% of patients with follicular lymphoma who were previously sensitive to rituximab become 'resistant' to repeat rituximab therapy.
  • 2nd/3rd generation anti-CD20s), and to identify additional potential targets on lymphoma cells other than CD20.
  • A number of these antibodies directed against lymphoma cell targets other than CD20 are now undergoing development, many of which are currently in clinical trials.
  • This manuscript focuses on an overview of these 'non-anti-CD20' novel mAbs for NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neth J Med. 2009 Sep;67(8):309-10 [19767656.001]
  • (PMID = 19767657.001).
  • [ISSN] 1872-9061
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, CD2; 0 / Antigens, CD30; 0 / Antigens, CD40; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 0 / Immunologic Factors; 0 / epratuzumab; 0 / lumiliximab; 0 / zanolimumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 119
  •  go-up   go-down


51. Otsuka T, Noda T, Yokoo M, Ibaraki K: Recurrent gastric perforation as a late complication of radiotherapy for mucosa-associated lymphoid tissue lymphoma of the stomach. Intern Med; 2008;47(15):1407-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent gastric perforation as a late complication of radiotherapy for mucosa-associated lymphoid tissue lymphoma of the stomach.
  • Radiation therapy can be used to treat Helicobacter pylori-negative or eradication-refractory extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) of the stomach.
  • We report a case of gastric perforation which occurred more than 1 year after the completion of radiotherapy for H. pylori eradication-refractory gastric MALT lymphoma, and then recurred shortly afterwards.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy. Radiation Injuries / diagnosis. Radiotherapy / adverse effects. Stomach / injuries. Stomach Neoplasms / radiotherapy


52. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA: Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma; 2010 Jan;51(1):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor.
  • Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chromosome Deletion. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 17. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Thalidomide / analogs & derivatives

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Jan;51(1):3-4 [20001866.001]
  • (PMID = 20055660.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


53. Antoniu SA: Treatment options for refractory Wegener's granulomatosis: a role for rituximab? Curr Opin Investig Drugs; 2007 Nov;8(11):927-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for refractory Wegener's granulomatosis: a role for rituximab?
  • Rituximab, a mAb which targets CD20+ B-cells, is currently used in the treatment non-Hodgkin's lymphoma and rheumatoid arthritis, and is being investigated for refractory WG therapy and other autoimmune diseases.
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Hematopoietic Stem Cell Transplantation / methods. Humans. Plasmapheresis / methods. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979026.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 84
  •  go-up   go-down


54. Brice P: Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol; 2008 Apr;141(1):3-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing relapsed and refractory Hodgkin lymphoma.
  • Despite a high curability rate, some patients with Hodgkin lymphoma (HL) fail to respond to, or relapse after, primary conventional treatment.
  • This enables relapsing patients to be separated in to three different prognostic groups; primary refractory patients should be included in the unfavourable group because of their poor prognosis.
  • Benefit of autologous stem-cell transplantation (ASCT) has been shown in a large randomized study and, although is often proposed in relapsed HL, it may be not necessary in the rare group of patients with stage I/II and late relapse who can receive additional radiotherapy after response to chemotherapy.
  • For patients in the unfavourable group, including refractory patients, the role of tandem HDT or allogeneic SCT will be discussed and should be proposed for patients not in complete remission at the time of HDT.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Practice Guidelines as Topic. Prognosis. Recurrence. Salvage Therapy / methods. Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279457.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


55. Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA: CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res; 2009 Apr 15;15(8):2739-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: CD20-directed therapy with rituximab is effective in many patients with malignant lymphoma or follicular lymphoma.
  • However, relapse frequently occurs within 1 year, and patients become increasingly refractory to retreatment.
  • Our purpose was to produce a compact, single-chain CD20-targeting immunotherapeutic that could offer therapeutic advantages in the treatment of B-cell lymphoma.
  • TRU-015 induced growth arrest in multiple B lymphoma cell lines in vitro and showed effective antitumor activity against large, established subcutaneous Ramos or Daudi xenograft tumors in nude mice.
  • [MeSH-major] Antigens, CD20 / immunology. B-Lymphocytes / drug effects. Lymphocyte Depletion. Lymphoma, B-Cell / therapy. Recombinant Fusion Proteins / therapeutic use. Recombinant Proteins / therapeutic use
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antibody-Dependent Cell Cytotoxicity / immunology. Cell Line, Tumor. Female. Humans. Macaca fascicularis. Male. Mice. Mice, Nude. Rituximab. Transplantation, Heterologous / immunology

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19351771.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 0 / TRU-015 protein; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


56. Huang Z, Higgins B, Foss F: Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clin Lymphoma; 2005 Jun;6(1):43-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of gallium nitrate in refractory peripheral T-cell lymphoma.
  • Peripheral T-cell lymphomas (PTCLs) are post-thymic malignancies characterized by an aggressive clinical course and an inferior outcome with standard therapies.
  • The authors report significant clinical activity of infusional gallium nitrate in a patient with stage IV PTCL disease refractory to chemotherapy.
  • [MeSH-major] Gallium / therapeutic use. Lymphoma, T-Cell / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989706.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 13494-90-1 / gallium nitrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


57. Chen CH, Chen SW, Shen WL, Chen TY, Tsao CJ, Huang WT: Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Int J Hematol; 2007 Feb;85(2):105-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
  • Anaplastic lymphoma kinase (ALK) expression exists in approximately 60% of anaplastic large cell lymphoma (ALCL) cases.
  • In the relapsed or refractory ALCL cases, high-dose chemotherapy followed by autologous stem cell transplantation has been widely used as a salvage therapy.
  • However, 40% of patients who received transplants after more than 2 complete remissions eventually experienced disease progression, despite receiving autologous stem cell transplantation.
  • Allogeneic stem cell transplantation has been proposed as a therapeutic option in refractory ALCL cases, but clinical reports of adult patients are rare.
  • Herein, we report the case of an adult with refractory ALK-positive ALCL who was successfully treated with salvage high-dose chemotherapy followed by allogeneic stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Haematologica. 2005 Mar;90(3):ECR19 [15753060.001]
  • [Cites] Lancet Oncol. 2004 Feb;5(2):127-8 [14761818.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1643-7 [16049513.001]
  • [Cites] Bone Marrow Transplant. 1999 Mar;23(5):437-42 [10100556.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1243-8 [8608211.001]
  • [Cites] J Formos Med Assoc. 1998 Feb;97(2):123-6 [9509848.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):657-60 [2156024.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):741-60 [11564061.001]
  • [Cites] Eur J Haematol. 2005 Jul;75(1):22-6 [15946306.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):736-42 [10929023.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):82-9 [7817951.001]
  • [Cites] Leuk Lymphoma. 1999 Sep;35(1-2):159-69 [10512173.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Leuk Lymphoma. 1996 Sep;23(1-2):25-32 [9021682.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • (PMID = 17321986.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1; CVAD protocol
  •  go-up   go-down


58. Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S, Potter M, Kazmi M, Gribben JG, Marks DI: The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology; 2008 Apr;13(2):119-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study.
  • Lymphoplasmacytic lymphoma (LL) is incurable by standard therapy (median survival: 60 months).
  • Disease status at transplant was complete remission (2), partial remission (5), primary refractory (1) or relapse (1).
  • Disease status at transplant was partial remission (7) or primary refractory (2).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Waldenstrom Macroglobulinemia / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616880.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Chumsri S, Zhao M, Garofalo M, Burger A, Hamburger A, Zhao F, Rapoport A: Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Leuk Lymphoma; 2008 Feb;49(2):359-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / drug therapy. Protein Kinases / drug effects. Sirolimus / therapeutic use. Skin Neoplasms / drug therapy


60. Leonard JP: Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology Am Soc Hematol Educ Program; 2005;:335-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab (chimeric anti-CD20 monoclonal antibody) is widely employed in the treatment of patients with B cell non-Hodgkin lymphoma (NHL).
  • Other studies in NHL have clearly demonstrated that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease, and have potential utility as part of initial treatment as well.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304400.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16814
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Iodine Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


61. Zain J, Rotter A, Weiss L, Forman S, Kirschbaum MH: Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1216-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma.
  • [MeSH-major] Drug Resistance, Neoplasm / drug effects. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Valproic Acid / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Leuk Lymphoma. 2007 Jul;48(7):1459
  • (PMID = 17577787.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


62. Macklis RM: Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S4-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both of these compounds produce impressive clinical results when used in the management of indolent, refractory, and transformed CD-20+ B-cell non-Hodgkin's lymphoma, but the unsealed sources involved in this class of compounds also require new types of patient care coordination and patient/environmental safety procedures.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Patient Care Team / organization & administration. Radioimmunotherapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Humans. Interprofessional Relations. Lymphoma, B-Cell / radiotherapy. Medical Oncology / organization & administration. Radiation Oncology / organization & administration. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979439.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody
  •  go-up   go-down


63. Christian BA, Grever MR, Byrd JC, Lin TS: Flavopiridol in chronic lymphocytic leukemia: a concise review. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S179-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the implementation of a standardized protocol to prevent severe TLS, flavopiridol was administered safely, and responses were observed in heavily pretreated, fludarabine-refractory patients, cytogenetically high-risk patients, and patients with bulky lymphadenopathy.
  • [MeSH-major] Flavonoids / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Piperidines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778838.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U01 CA76576; United States / NCI NIH HHS / CA / K23 CA102276; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / R21 CA112947-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Flavonoids; 0 / Piperidines; 45AD6X575G / alvocidib
  • [Number-of-references] 52
  •  go-up   go-down


64. Bommer M, von Harsdorf S, Döhner H, Bunjes D, Ringhoffer M: Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation. Haematologica; 2010 Nov;95(11):1969-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation.
  • We analyzed the frequency of neoplastic meningitis in patients with acute myeloid leukemia prior to allogeneic hematopoietic stem cell transplantation at our institution.
  • Between 1996 and 2009, cerebrospinal fluid samples of 204 adult patients were examined during pre-transplant work-up for cell counts and, if abnormal, morphologically.
  • The proportion of patients with central nervous system involvement was significantly higher in patients with refractory disease at the time of transplantation compared with patients responding to prior systemic therapy (19% vs. 4.6%; P=0.003).
  • Since most of the patients with central nervous system involvement were asymptomatic, cerebrospinal fluid evaluation should be considered at least in patients with refractory acute myeloid leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Meningeal Neoplasms / mortality. Meningeal Neoplasms / therapy


65. Yamaguchi Y, Usui N: [Malignant lymphomas]. Gan To Kagaku Ryoho; 2009 May;36(5):736-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, treatment for relapsed or refractory lymphoma has not been fully established.
  • As second-line therapy for patients with relapsed/refractory follicular lymphoma or diffuse large B cell lymphoma, chemotherapy including alkylating agents or purine analogues, high-dose chemotherapy followed by autologous stem cell transplantation (SCT), and allogeneic SCT are usually selected.
  • [MeSH-major] Lymphoma / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Immunotherapy. Recurrence. Stem Cell Transplantation. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461173.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter JN, Nademanee A: Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan. Curr Stem Cell Res Ther; 2007 Sep;2(3):239-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
  • Although autologous stem cell transplantation (ASCT) produces prolonged disease-free survival in many patients with non-Hodgkin's lymphoma (NHL), relapse remains the most common cause of treatment failure.
  • Current strategies include using standard or escalated doses of radioimmunoconjugates with HDC before ASCT in patients with relapsed or refractory B-cell NHL.
  • Preliminary data from phase 1 and 2 trials show that (90)Y ibritumomab tiuxetan may be safely added to HDC preparative regimens for high-risk B-cell NHL.
  • Studies of (90)Y ibritumomab tiuxetan in the setting of allogeneic stem cell transplantation appear promising as well.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220907.001).
  • [ISSN] 1574-888X
  • [Journal-full-title] Current stem cell research & therapy
  • [ISO-abbreviation] Curr Stem Cell Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Number-of-references] 23
  •  go-up   go-down


72. Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ: Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer; 2008 Mar;50(3):667-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
  • We report a novel regimen for refractory post-transplant T-cell lymphoma (PTL).
  • Our patient presented with non-Epstein-Barr virus (EBV) related, T-cell post-transplant lymphoproliferative disease (PTLD) 3.5 years after liver transplantation.
  • Initially diagnosed as polyclonal PTLD, the disease progressed to a monoclonal, T-cell PTL that was refractory to several chemotherapy regimens but responded to a regimen consisting of fludarabine, cyclophosphamide, cytarabine, and alemtuzumab.
  • Consolidation therapy included high-dose chemotherapy, autologous hematopoietic stem cell rescue, and radiation therapy.
  • T-cell PTL is a rare disease with a poor prognosis; this regimen provides a novel, potentially curative approach for its treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Transplantation. Lymphoma, T-Cell, Peripheral / therapy. Lymphoproliferative Disorders / therapy. Postoperative Complications / therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / administration & dosage. Biliary Atresia / surgery. Carboplatin / administration & dosage. Carmustine / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Transplantation. Humans. Ifosfamide / administration & dosage. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Melphalan / administration & dosage. Mesna / administration & dosage. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Transplantation, Autologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17318876.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A189DH42V / alemtuzumab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; FA2DM6879K / Vidarabine; NR7O1405Q9 / Mesna; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; BEAM regimen; EPOCH protocol; ICE protocol 5
  •  go-up   go-down


73. Kwong YL: High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant; 2009 Dec;44(11):709-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies.
  • Natural killer (NK)-cell lymphomas are aggressive.
  • Patients with advanced, relapsed or refractory diseases had dismal survivals after autologous HSCT.
  • To evaluate the efficacy of allogeneic HSCT, optimal conditioning regimens and a clear graft-versus-lymphoma effect should be defined.
  • HSCT is a potential option in NK-cell lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Extranodal NK-T-Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767784.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


74. Puig N, Pintilie M, Seshadri T, Al-Farsi K, Nagy T, Franke N, Tsang R, Keating A, Crump M, Kuruvilla J: Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica; 2010 Sep;95(9):1496-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.
  • BACKGROUND: The use of high-dose chemotherapy and autologous stem-cell transplantation in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials but its benefit in patients with primary refractory disease is less clear.
  • Aiming to shed light on this issue, we analyzed and compared the outcomes of patients with relapsed or refractory Hodgkin's lymphoma treated with second-line chemotherapy and planned autologous stem-cell transplantation.
  • DESIGN AND METHODS: We retrospectively analyzed data on 157 consecutive patients with Hodgkin's lymphoma referred to our institution for consideration of autologous stem-cell transplantation between 1999 and 2006.
  • Of those, 73 met the definition of having primary refractory disease, ie. progressive disease during first line chemotherapy or within 3 months of completion of the treatment.
  • Those patients achieving complete remission, partial remission and stable disease with symptomatic improvement after two or three cycles of salvage chemotherapy proceeded to stem cell mobilization and autologous transplantation.
  • RESULTS: From first relapse/progression, the 3-year overall survival was 76% (95% CI: 66%-89%) for the refractory cohort and 91% (95% CI: 84%-98%) for the relapsed cohort (P=0.034); the overall response rate to second-line chemotherapy was 51% and 83% (P<0.0001), respectively.
  • Three-year progression-free survival post-transplant was 49% in refractory patients and 67% in relapsed patients (P=0.21); overall survival was 75% and 91% (P=0.097), respectively.
  • CONCLUSIONS: Using the group with relapsed disease as a reference, we can conclude that the subset of patients with chemosensitive primary refractory Hodgkin's lymphoma do benefit from autologous stem-cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):332-9 [10637247.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):972-80 [10694546.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:81-5 [10707785.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):161-71 [11328296.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):467-75 [11786576.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Bone Marrow Transplant. 2002 Sep;30(5):273-8 [12209348.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1762-7 [14630682.001]
  • [Cites] Br J Haematol. 2004 Mar;124(5):645-52 [14871252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):208-18 [15093918.001]
  • [Cites] Bone Marrow Transplant. 2004 Jun;33(12):1225-9 [15094747.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):47-50 [3041599.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 1991 May 15;77(10):2292-8 [1709382.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):210-8 [1732422.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1137-45 [8443375.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):704-11 [8478664.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):396-402 [7844600.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1293-9 [8826953.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):528-34 [9053474.001]
  • [Cites] Blood. 1997 Feb 1;89(3):801-13 [9028311.001]
  • [Cites] Blood. 1997 Feb 1;89(3):814-22 [9028312.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1638-45 [9193364.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):534-45 [10080597.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):73-8 [10211091.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):222-9 [10458237.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3101-9 [10506605.001]
  • [Cites] Bone Marrow Transplant. 2005 Feb;35(3):291-8 [15558040.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4634-42 [15837968.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):353-60 [16329112.001]
  • [Cites] Bone Marrow Transplant. 2007 Oct;40(7):651-8 [17660837.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5980-7 [19018090.001]
  • (PMID = 20460643.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2930950
  •  go-up   go-down


75. Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E: Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging; 2009 Nov;36(11):1745-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
  • PURPOSE: The aim of this study was to carry out two different dose estimation approaches in patients with non-Hodgkin's lymphoma (NHL) treated with a myeloablative amount of (90)Y-labelled ibritumomab tiuxetan (Zevalin(R)) in an open-label dose escalation study.
  • METHODS: Twenty-seven patients with relapsed/refractory or de novo high-risk NHL receiving one myeloablative dose of (90)Y-ibritumomab tiuxetan followed by tandem stem cell reinfusion were evaluated for dose estimate.
  • No non-haematological toxicity (liver, kidney, lung) was observed during a follow-up period of 24-48 months.
  • CONCLUSION: The use of 45 MBq/kg of (90)Y-ibritumomab tiuxetan in association with stem cell autografting resulted in patients being free of toxicity in non-haematological organs.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radiation Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1263-70 [12663713.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Aug;17(4):445-64 [12396708.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10):1679-86 [16204718.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Oct;23 (5):633-9 [18999935.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Oct;17(5):535-43 [12470423.001]
  • [Cites] Phys Med Biol. 1996 Oct;41(10):1871-84 [8912367.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Feb;22(1):113-20 [17627419.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:99S-106S [15653658.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):590-9 [17979944.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5175-82 [18854569.001]
  • [Cites] Med Phys. 2005 Jul;32(7):2399-405 [16121597.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] J Nucl Med. 2003 Mar;44(3):465-74 [12621016.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1023-7 [15937315.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):616-22 [17323056.001]
  • [Cites] Lancet. 1989 Sep 9;2(8663):580-5 [2570283.001]
  • [Cites] Clin Lymphoma. 2004 Sep;5(2):98-101 [15453924.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1374-8 [9293790.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Aug;19(4):478-81 [15453962.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Oct;22(5):684-91 [17979571.001]
  • [Cites] J Nucl Med. 2005 May;46(5):899-900; author reply 901 [15872367.001]
  • [Cites] J Nucl Med. 2007 Nov;48(11):1871-9 [17978355.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Apr;20(2):126-40 [15869446.001]
  • [Cites] Blood. 2004 Jun 15;103(12 ):4429-31 [15016644.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94 [11418315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):1981-97 [6759484.001]
  • [Cites] J Nucl Med. 1999 Feb;40(2):37S-61S [10025848.001]
  • [Cites] J Nucl Med. 1996 Mar;37(3):538-46 [8772664.001]
  • [Cites] J Nucl Med. 1998 Dec;39(12):2167-72 [9867163.001]
  • [Cites] J Nucl Med. 2008 Feb;49(2):279-84 [18199606.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 19455328.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 4Q52C550XK / ibritumomab tiuxetan
  •  go-up   go-down


76. Tsartsidze E, Betaneli M, Sharikadze N, Shavidze N, Seskuria N: Treatment of aggressive non-Hodgkin's lymphomas. Georgian Med News; 2007 Apr;(145):30-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of aggressive non-Hodgkin's lymphomas.
  • 27 patients with diagnosis of diffuse large B-cell lymphomas were under observation.
  • I- primary refractory patients who undergone chemotherapy with CHOP regimen (9 patents); II - patients refractory to the standard added intensive chemotherapy regimens (BEAM) (10 patients).
  • In summary based on our observations quantity of unfavorable prognostic factors may determine primary refractory patients to standard therapies and first line treatment in CD20 positive cases with CHOP plus Rituximab regimen increased overall survival from 7,4 month to 17 month (p<0,01).
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525494.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


77. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R: Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1183-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.
  • PURPOSE: Patients with chemotherapy-resistant lymphoma have rapidly progressive disease and a poor prognosis.
  • The histologic features at diagnosis were follicular in 11 (Grade 1 in 4, Grade 2 in 3, and Grade 3 in 4), diffuse large B-cell in 14, peripheral T-cell lymphoma in 2, Burkitt-like in 1, mantle cell in 2, natural killer cell in 2, plasmacytoma/lymphoma in 1, and T-cell lymphoblastic in 1.
  • The initial treatment was chemotherapy in 32 patients (94%); 71% were refractory to initial chemotherapy and 29% developed a relapse after an initial response.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376490.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Feist E, Hermann KG, Dankof A: [Vasculopathy in Sjögren's syndrome]. Z Rheumatol; 2009 Jun;68(4):305-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the pathogenesis of vasculitis, B-cell-driven autoimmune processes play a major role by producing autoantibodies against the Ro/SS-A and La/SS-B antigens and cryoglobulins.
  • In patients with Sjögren's syndrome, manifestation of vasculitis, non-Hodgkin's lymphoma and glomerulonephritis, as well as positive cryoglobulins and decreased levels of complement factors, are considered negative prognostic markers.
  • For refractory and severe manifestations, a B-cell-targeted therapy with Rituximab should be also considered.

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 2004 Aug;43(8):1050-3 [15187246.001]
  • [Cites] Ann Intern Med. 1983 Feb;98(2):155-9 [6600593.001]
  • [Cites] Br J Rheumatol. 1990 Feb;29(1):21-3 [2155037.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Aug;11(8):931-4 [10514131.001]
  • [Cites] Neurology. 1981 Nov;31(11):1391-6 [6273765.001]
  • [Cites] Medicine (Baltimore). 2004 Sep;83(5):280-91 [15342972.001]
  • [Cites] J Rheumatol. 2002 Apr;29(4):726-30 [11950013.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Jul;80(1):55-66 [8674240.001]
  • [Cites] Pathologe. 2006 Nov;27(6):416-21 [17039338.001]
  • [Cites] Medicine (Baltimore). 2004 Mar;83(2):96-106 [15028963.001]
  • [Cites] Arthritis Rheum. 2004 Apr;50(4):1262-9 [15077310.001]
  • [Cites] Semin Arthritis Rheum. 2007 Feb;36(4):246-55 [16996579.001]
  • [Cites] Neurology. 1997 Apr;48(4):855-62 [9109867.001]
  • [Cites] Am J Clin Pathol. 1987 Jul;88(1):26-31 [3604987.001]
  • [Cites] Lupus. 1998;7(4):231-4 [9643312.001]
  • [Cites] Medicine (Baltimore). 1982 Jul;61(4):247-57 [6283302.001]
  • [Cites] Ann Rheum Dis. 2008 Nov;67(11):1541-4 [18276741.001]
  • [Cites] Ann Neurol. 1982 Jun;11(6):632-5 [6126150.001]
  • [Cites] Pathologe. 2003 May;24(3):165-81 [12739050.001]
  • [Cites] Arthritis Rheum. 2007 Dec 15;57(8):1520-9 [18050172.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2740-50 [16142737.001]
  • [Cites] J Rheumatol. 2000 Nov;27(11):2611-6 [11093441.001]
  • [Cites] Scand J Rheumatol. 1996;25(5):271-6 [8921918.001]
  • [Cites] Brain. 2005 Nov;128(Pt 11):2518-34 [16049042.001]
  • [Cites] Semin Arthritis Rheum. 2006 Apr;35(5):312-21 [16616154.001]
  • [Cites] Arthritis Rheum. 2005 Dec;52(12):3890-7 [16320337.001]
  • [Cites] Arthritis Rheum. 2004 Mar;50(3):882-91 [15022331.001]
  • [Cites] Semin Arthritis Rheum. 2000 Apr;29(5):296-304 [10805354.001]
  • [Cites] Clin Rheumatol. 2008 Dec;27(12):1479-83 [18553114.001]
  • [Cites] Arthritis Rheum. 1996 May;39(5):767-72 [8639173.001]
  • [Cites] Medicine (Baltimore). 2008 Jul;87(4):210-9 [18626304.001]
  • [Cites] Ann Rheum Dis. 1999 Jul;58(7):415-22 [10381485.001]
  • [Cites] Ann Rheum Dis. 2007 Aug;66(8):1026-32 [17223657.001]
  • [Cites] Rheumatology (Oxford). 2006 Apr;45(4):481-4 [16303821.001]
  • [Cites] Scand J Immunol. 2008 Dec;68(6):554-64 [19000095.001]
  • [Cites] J Clin Pathol. 1968 Sep;21(5):656-60 [5697370.001]
  • [Cites] Arthritis Rheum. 2003 Nov;48(11):3187-201 [14613282.001]
  • [Cites] Ann Rheum Dis. 2006 Jun;65(6):796-803 [16284097.001]
  • [Cites] Rheumatology (Oxford). 2007 Aug;46(8):1359-62 [17569749.001]
  • [Cites] Arthritis Rheum. 2002 Mar;46(3):741-7 [11920410.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2007 Dec;21(6):989-1010 [18068857.001]
  • (PMID = 19357858.001).
  • [ISSN] 1435-1250
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 43
  •  go-up   go-down


79. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS: A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma; 2010 Mar;51(3):447-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
  • The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable.
  • Patients with newly diagnosed (n = 27) or refractory/relapsed (n = 11) PTCL received a combination of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin.
  • In relapsed/refractory patients the median OS was 6.1 months.
  • Treatment-related deaths occurred in six newly diagnosed patients and one with relapsed/refractory disease.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, T-Cell / drug therapy. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141439.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


80. Vakiani E, Arguelles-Grande C, Mansukhani MM, Lewis SK, Rotterdam H, Green PH, Bhagat G: Collagenous sprue is not always associated with dismal outcomes: a clinicopathological study of 19 patients. Mod Pathol; 2010 Jan;23(1):12-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small bowel histology, including thickness of subepithelial collagen, intra-epithelial lymphocyte phenotype and results of T-cell clonality assays were evaluated.
  • Seventeen (89%) had celiac disease and two had unclassified sprue; 9 of 17 (53%) celiac disease patients had refractory disease; 5 of 15 (33%) lacked diarrhea (atypical presentation), including 2 of 6 (33%) with active (untreated) celiac disease and 3 of 9 (33%) with refractory celiac disease.
  • Polymerase chain reaction analysis showed a dominant T-cell clone in the only patient with refractory celiac disease type II.
  • Overall, 8 of 19 (42%) responded to gluten-free diet, including 2 of 9 (22%) with refractory celiac disease and 10 responded to immunomodulatory therapy, including 6 of 9 (67%) with refractory celiac disease.
  • Only one patient died from complications of refractory celiac disease.
  • No patient developed lymphoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Separation. Female. Flow Cytometry. Humans. Immunohistochemistry. Male. Middle Aged. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855376.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC: Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol; 2010 Nov 20;28(33):4919-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
  • We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia.
  • CONCLUSION: Lenalidomide was safely escalated to 50 mg daily for 21 days, every 4 weeks, and was active with relatively low toxicity in patients with relapsed/refractory AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thalidomide / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1):61-7 [16399569.001]
  • [Cites] Br J Cancer. 2005 Sep 19;93(6):613-9 [16222306.001]
  • [Cites] Blood. 2006 Jul 15;108(2):618-21 [16569772.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1456-65 [17021321.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11 [17576924.001]
  • [Cites] J Clin Pharmacol. 2007 Dec;47(12):1466-75 [17954615.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):36-45 [17995965.001]
  • [Cites] Blood. 2008 Jan 1;111(1):86-93 [17893227.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4650-7 [18628480.001]
  • [Cites] Cancer Immunol Immunother. 2008 Dec;57(12):1849-59 [18392823.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1002-5 [18824593.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6250-5 [19332800.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3947-52 [18987358.001]
  • [Cites] J Clin Pharmacol. 2009 Jun;49(6):650-60 [19451403.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9 [19470455.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4027-33 [19710500.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):217-25 [19804455.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):596-604 [20026798.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):556-61 [20026803.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):549-55 [20026805.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1204-13 [19965644.001]
  • [Cites] Blood. 2010 Mar 11;115(10):2077-87 [20053754.001]
  • [Cites] Blood. 2010 Apr 1;115(13):2619-29 [19965642.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8 [20368434.001]
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2389-95 [20385984.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(11):1157-63 [11149725.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 1997 Jun 1;89(11):4226-35 [9166868.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S9-12 [9272127.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):965-70 [15806131.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 5):S24-30 [16085014.001]
  • [Cites] Future Oncol. 2005 Oct;1(5):575-83 [16556034.001]
  • (PMID = 20956622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA140158; United States / NCI NIH HHS / CA / K23 CA120708; United States / NCI NIH HHS / CA / P50-CA140158; United States / NCI NIH HHS / CA / K23CA120708; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / P30 CA016058
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ PMC3020696
  •  go-up   go-down


82. Verbeek WH, von Blomberg BM, Scholten PE, Kuik DJ, Mulder CJ, Schreurs MW: The presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease. Am J Gastroenterol; 2008 Dec;103(12):3152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease.
  • BACKGROUND: In refractory celiac disease (RCD) type II, a phenotypically aberrant (CD7+ CD3- CD4/8-cytoplasmicCD3+) intraepithelial lymphocyte (IEL) population is present, and 50-60% of these patients develop enteropathy-associated T-cell lymphoma (EATL).
  • [MeSH-major] Celiac Disease / immunology. Intestine, Small / immunology. Lymphoma / immunology. Receptors, Antigen, T-Cell, gamma-delta / immunology. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19086962.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


83. Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, Yavuzsen T, Yuksel E, Undar B: The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymphoma; 2007 Jul;48(7):1372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In WHO classification, significant differences were observed in both OS and leukaemia free survival (LFS) between patients with RA/RARS and refractory cytopenia with multi-lineage dysplasia/refractory cytopenia with multi-lineage dysplasia and ringed sideroblasts (RCMD/RS-RCMD) (p = 0.0001).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Classification. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Turkey / epidemiology. World Health Organization


84. Han AR, Kim K, Jang JH, Kim WS, Ahn JS, Jung CW, Lee MH, Kang WK: Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia. J Korean Med Sci; 2008 Apr;23(2):278-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-three patients (92%) achieved a complete remission (CR), and two patients (8%) had refractory disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Oct;27(5):540-59 [11049022.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33(5):359-65 [8306408.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1353-66, x [11147227.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1367-79, x [11147228.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi [11147229.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):297-307 [11378542.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):748-54 [12181041.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jun;25(6):484-7 [12794528.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):994-1004 [2189958.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] J Investig Med. 1996 Dec;44(9):522-30 [9035605.001]
  • [Cites] Hematol Oncol. 1997 Feb;15(1):19-26 [9378468.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1556-64 [9716583.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7161-7 [16192600.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2007 Feb;21(2):238-47 [17170721.001]
  • [Cites] Blood. 2007 May 15;109(10):4164-7 [17264295.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1327-52 [11147226.001]
  • (PMID = 18437012.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC2526435
  •  go-up   go-down


85. Latifzadeh SZ, Entezari V: Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report. Clin Appl Thromb Hemost; 2006 Oct;12(4):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
  • CD20, a trans-membrane B-cell-specific antigen, is a potential target for treatment of certain malignant and nonmalignant plasma cell disorders including refractory ITP.
  • Rituximab is a genetically engineered human anti-CD20 monoclonal antibody, which is approved for the treatment of low-grade non-Hodgkin's lymphoma.
  • Recent clinical reports suggest that rituximab may be useful in treating certain patients with chronic refractory ITP.
  • A 59-year-old woman with refractory ITP was placed on rituximab (four weekly doses of 375 mg/m(2)) and her condition and platelet count were observed for 18 months.
  • Anti-CD20 antibodies are likely to be used in the treatment of refractory ITP cases, but further studies about treatment schedule and criteria for patient selection should be done.

  • Genetic Alliance. consumer health - Idiopathic thrombocytopenic purpura.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000895.001).
  • [ISSN] 1076-0296
  • [Journal-full-title] Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • [ISO-abbreviation] Clin. Appl. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antirheumatic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


86. Houghton PJ: Everolimus. Clin Cancer Res; 2010 Mar 01;16(5):1368-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Food and Drug Administration for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial growth factor (VEGF) receptor signaling.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Sirolimus / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Leuk Lymphoma. 2009 Dec;50(12):1916-30 [19757306.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):153-5 [16530700.001]
  • [Cites] Genes Dev. 2008 Jan 15;22(2):239-51 [18198340.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1603-10 [18332469.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13907-17 [11847216.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29655-60 [12777372.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3500-7 [15150104.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):519-23 [15193254.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Genes Dev. 2004 Dec 1;18(23):2893-904 [15545625.001]
  • [Cites] Nature. 2005 Feb 3;433(7025):477-80 [15690031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9 [15928081.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1588-95 [18332470.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1612-22 [19223496.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):742-53 [19372546.001]
  • [Cites] Ann Oncol. 2009 Oct;20(10):1674-81 [19549709.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7662-71 [19789339.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4536-41 [19687332.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • (PMID = 20179227.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077776; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P01 CA023099-310011; United States / NCI NIH HHS / CA / CA77776; United States / NCI NIH HHS / CA / R01 CA077776-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 23
  • [Other-IDs] NLM/ NIHMS167833; NLM/ PMC3003868
  •  go-up   go-down


87. Xu YC, Lin YM, Zhang FC: [The relationship between abnormal MDR gene expression and chemotherapy response in lymphoid malignancies]. Zhonghua Zhong Liu Za Zhi; 2006 May;28(5):353-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) The expressions of MDR(1), Topo II, GCR in untreated and relapsed/refractory patients with ALL, NHL, NHL-L, MM were significantly abnormal at varying levels, especially in the relapsed/refractory group. (2) The complete remission (CR) rate of MDR(1) high expression group (MDR(1)(+)) was significantly lower than that of MDR(1) negative expression (MDR(1)(-)) group (P < 0.05), and the relapse rate of MDR(1)(+) group was significantly higher than that of MDR(1)(-) group (P < 0.05).
  • In untreated patients, the relapse rate in the Topo II low expression (Topo II(-)) group was positively higher than Topo II high expression (Topo II(+)) group (P < 0.05), whereas in the relapsed/refractory patients, the CR rate of Topo II(-) group was significantly lower than that of Topo II(+) group (P < 0.05).
  • In the untreated and relapsed/refractory patients, the CR rates of low GCR expression (GCR(-)) group was obviously lower than that in the normal GCR expression group (P < 0.05). (3) Considering mono-drug resistance mechanism, CR rate of MDR(1)(+) group was the lowest, Topo II(-) group took the second place and GCR(-) group was the highest.
  • [MeSH-major] DNA Topoisomerases, Type II / metabolism. Lymphoma, Non-Hodgkin / metabolism. P-Glycoprotein / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, Glucocorticoid / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044999.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / Receptors, Glucocorticoid; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


88. Yamada S, Tanimoto A, Matsuki Y, Hisada Y, Sasaguri Y: Sclerosing encapsulating peritonitis (abdominal cocoon) associated with liver cirrhosis and diffuse large B-cell lymphoma: autopsy case. Pathol Int; 2009 Sep;59(9):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing encapsulating peritonitis (abdominal cocoon) associated with liver cirrhosis and diffuse large B-cell lymphoma: autopsy case.
  • A case of sclerosing encapsulating peritonitis (SEP) associated with liver cirrhosis (LC) and complicated by diffuse large B-cell lymphoma (DLBCL) is reported herein.
  • A 49-year-old Japanese man had undergone peritoneo-venous shunt against refractory ascites due to hepatitis C virus-positive uncompensated LC for 2 years.
  • [MeSH-major] Liver Cirrhosis / complications. Lymphoma, Large B-Cell, Diffuse / complications. Peritonitis / etiology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19712139.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


89. Hacihanefioglu A, Tarkun P, Gonullu E: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol; 2008 Sep;88(2):219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phase II clinical trials demonstrate that it is effective for the treatment of relapsed refractory myeloma.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Dec 18;426(6968):895-9 [14685250.001]
  • [Cites] Cancer Control. 2003 Sep-Oct;10(5):361-9 [14581890.001]
  • [Cites] Cardiovasc Res. 2006 Jun 1;70(3):410-21 [16497285.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):253-62 [16787504.001]
  • [Cites] Br J Haematol. 2007 Aug;138(3):396-7 [17561972.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Sep;7(2):131-4 [17026824.001]
  • [Cites] Oncologist. 2007 Jun;12(6):664-89 [17602058.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H1-H19 [16501026.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27549-59 [15102862.001]
  • [Cites] Cardiovasc Res. 2004 Jan 1;61(1):11-21 [14732197.001]
  • [Cites] Leukemia. 2002 Apr;16(4):433-43 [11960320.001]
  • [Cites] J Mol Cell Cardiol. 2006 Oct;41(4):567-79 [16949602.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2615-22 [10363983.001]
  • [Cites] BMC Cancer. 2006 May 11;6:129 [16689991.001]
  • [Cites] Cancer Biol Ther. 2003 Nov-Dec;2(6):694-9 [14688479.001]
  • [Cites] Oncologist. 2007 Jan;12(1):99-106 [17227904.001]
  • (PMID = 18633693.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


90. Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA: Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma; 2010 Aug;51 Suppl 1:1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel disease targets and management approaches for diffuse large B-cell lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) responds well to treatment with CHOP and the R-CHOP regimen, but a subset of patients still fail to achieve complete or durable responses.
  • Recent advances in gene expression profiling have led to the identification of three different subtypes of DLBCL, and confirmed that patients with the activated B-cell (ABC) disease subtype are less likely to respond well to CHOP-based regimens than those with germinal centre B-cell-type (GCB) disease.
  • Treatment options for patients with relapsed or refractory DLBCL are limited and several novel agents are being developed to address this unmet clinical need.
  • Novel agents developed to treat plasma cell disorders such as multiple myeloma have shown promising activity in patients with NHL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy


91. Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, Koral KF, Kaminski MS, Avram AM: 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med; 2010 Jul;51(7):1155-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty patients undergoing (131)I-tositumomab for the treatment of refractory B-cell lymphoma volunteered for the study.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1316-23 [10715303.001]
  • [Cites] J Nucl Med. 2010 Apr;51(4):654-9 [20237032.001]
  • [Cites] J Nucl Med. 2003 Feb;44(2):260-8 [12571219.001]
  • [Cites] J Nucl Med. 2003 Mar;44(3):457-64 [12621015.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1322-9 [12902424.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):4003S-6S [14506200.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):2000-18 [14660727.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1317-26 [10450684.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1337-41 [10450686.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7792-8 [15585610.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:18S-27S [15653648.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:92S-8S [15653657.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] J Nucl Med. 2005 May;46(5):840-9 [15872359.001]
  • [Cites] Phys Med Biol. 2006 Jul 7;51(13):R187-202 [16790903.001]
  • [Cites] Phys Med Biol. 2007 Feb 7;52(3):777-90 [17228120.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 May;34(5):772-86 [17268773.001]
  • [Cites] Cancer Biother Radiopharm. 2009 Aug;24(4):417-26 [19694576.001]
  • [Cites] J Nucl Med. 2001 Nov;42(11):1713-21 [11696644.001]
  • (PMID = 20554734.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB001994; United States / NIBIB NIH HHS / EB / R01 EB001994-11; United States / NIBIB NIH HHS / EB / 2R01 EB001994
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / iodine-131 anti-B1 antibody
  • [Other-IDs] NLM/ NIHMS359174; NLM/ PMC3302158
  •  go-up   go-down


92. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC: The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood; 2005 Jan 1;105(1):308-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) is a common and often fatal malignancy.
  • We previously defined an expression signature of outcome in DLBCL and found that the phosphodiesterase PDE4B was overexpressed in fatal/refractory tumors.
  • Herein, we confirmed the risk-related expression of PDE4B in an independent series of primary DLBCLs and defined the enzyme's role in modulating cAMP-induced apoptosis in parental DLBCL cell lines or those reconstituted with wild-type or mutant PDE4B.
  • [MeSH-major] 3',5'-Cyclic-AMP Phosphodiesterases / metabolism. Apoptosis. Cyclic AMP / metabolism. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / pathology. Phosphatidylinositol 3-Kinases / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Carrier Proteins. Caspase 3. Caspase 9. Caspases / metabolism. Cell Line, Tumor. Cyclic AMP-Dependent Protein Kinases / metabolism. Cyclic Nucleotide Phosphodiesterases, Type 4. Gene Expression Regulation, Neoplastic. Humans. Mitochondria / metabolism. Phosphorylation. Protein Isoforms / metabolism. Proto-Oncogene Proteins c-akt. Signal Transduction. bcl-Associated Death Protein

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15331441.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAD protein, human; 0 / Carrier Proteins; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / bcl-Associated Death Protein; E0399OZS9N / Cyclic AMP; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.1.4.17 / 3',5'-Cyclic-AMP Phosphodiesterases; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 4; EC 3.1.4.17 / PDE4B protein, human; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
  •  go-up   go-down


93. Menzel H, Müller A, Von Schilling C, Licht T, Peschel C, Keller U: Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization. Leuk Lymphoma; 2008 Jul;49(7):1337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization.
  • Chemotherapy with ifosfamide, epirubicin and etoposide (IEV) is an effective treatment regimen for refractory/relapsed non-Hodgkin lymphoma (NHL).
  • Rituximab has been shown to improve response rates, progression-free survival and overall survival in B-cell NHL.
  • This study included 85 patients who were treated with IEV or rituximab-IEV (R-IEV) for refractory/relapsed B-cell NHL.
  • The addition of rituximab to IEV salvage chemotherapy increases the response rates in B-cell NHL without affecting stem cell mobilization, but overall survival for patients proceeding to high-dose chemotherapy is not improved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Mobilization. Lymphoma, B-Cell / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Fever / chemically induced. Hematopoietic Stem Cell Transplantation. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Remission Induction. Rituximab. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604723.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


94. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S: Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer; 2006 Jun 15;106(12):2645-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Alemtuzumab is a humanized monoclonal antibody directed against the cell surface antigen CD52 and has demonstrated activity in chronic lymphocytic leukemia and other CD52-positive lymphoproliferative disorders.
  • METHODS: Fifteen patients with CD52-positive (> or = 20%), recurrent or refractory acute leukemia (9 patients with AML and 6 patients with ALL) received alemtuzumab at a dose of 30 mg intravenously given 3 times a week (dose escalation during Week 1) for a total of 4 to 12 weeks.
  • CONCLUSIONS: Single-agent alemtuzumab was found to have limited activity in recurrent or refractory acute leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16688777.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


95. Mir MA, Agrewala JN: Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets; 2008 Aug;12(8):969-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Many reports have described the influence of CD80 on the growth of B cell and follicular lymphomas.
  • Signaling through CD80 in B cell lymphomas can retard their proliferation by upregulating expression of pro-apoptotic molecules and downregulating antiapoptotic molecules and can therefore induce apoptosis.
  • Recently, a Phase I/II study of treatment with CD80-specific antibody has shown it to be quite effective in relapsed and refractory follicular lymphoma patients.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Lymphoma / drug therapy. Oligopeptides / metabolism. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620519.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / CD80-CAP; 0 / Oligopeptides
  • [Number-of-references] 80
  •  go-up   go-down


96. Visser OJ, Perk LR, Zijlstra JM, van Dongen GA, Huijgens PC, van de Loosdrecht AA: Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease. BioDrugs; 2006;20(4):201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.
  • Recently, RIT has been introduced targeting the CD20 surface antigen, which is expressed on nearly all B-cell non-Hodgkin lymphomas (NHL).
  • In general, there is no organ-specific non-hematologic toxicity when a standard dose of RIT is used.
  • Randomized phase III studies are in progress to evaluate the timing of RIT in the overall management of indolent NHLInvestigations of new emerging therapeutic strategies for patients with indolent NHL are underway, with research into the feasibility of RIT as first-line therapy and in advanced disease, RIT dose escalation and combined modality approaches with autologous stem cell transplantation.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods


97. Bamba AV, Jadhav MP, Prabhu R, Ray S, Gogtay NJ, Jijina FF, Kshirsagar NA: Refractory hypokalemia due to conventional amphotericin B in patients with leukemia. Indian J Cancer; 2009 Jan-Mar;46(1):76-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory hypokalemia due to conventional amphotericin B in patients with leukemia.
  • [MeSH-major] Amphotericin B / adverse effects. Anti-Bacterial Agents / adverse effects. Drug Resistance. Hypokalemia / chemically induced. Leukemia, Myeloid, Acute / complications. Neutropenia / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Hypokalemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282576.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


98. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M: Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica; 2007 Jan;92(1):35-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Response to pre-transplant salvage chemotherapy remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin's lymphoma.
  • Results of a new induction regimen are reported in terms of response rates, toxicity, and stem cell mobilization.
  • DESIGN AND METHODS: Ninety-one patients with refractory or relapsed Hodgkin's lymphoma were treated prospectively with a salvage regimen consisting of ifosfamide 2000 mg/m2 on days 1 to 4, gemcitabine 800 mg/m2 on days 1 and 4, vinorelbine 20 mg/m2 on day 1, and prednisolone 100 mg on days 1 to 4 (IGEV).
  • Adequate CD34+ cell collection was achieved in 78 out of 79 (98.7%) mobilized patients.
  • No grade 4 non-hematologic toxicity was observed, except for one episode of mucositis.
  • INTERPRETATION AND CONCLUSIONS: The high response rate, in particular the complete remission rate, the low toxicity profile, and the very high mobilizing potential of the IGEV regimen strongly suggest that patients with relapsed/refractory Hodgkin's lymphoma may benefit from the use of this salvage induction regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Hodgkin Disease / drug therapy. Ifosfamide / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / biosynthesis. Female. Humans. Male. Middle Aged. Recurrence. Stem Cell Transplantation. Treatment Outcome


99. Tarrand JJ, Keating MJ, Tsimberidou AM, O'Brien S, LaSala RP, Han XY, Bueso-Ramos CE: Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer; 2010 Feb 15;116(4):880-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a later cohort of patients after hematopoietic stem cell transplantation, 4 of 7 patients with Hodgkin lymphoma or Burkitt lymphoma had EBV LMP1 detected.
  • Thus, EBV LMP1 expression in CLL patients may be a factor involved in the genesis of refractory disease.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / virology. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / metabolism. Bone Marrow / pathology. Bone Marrow / virology. Cell Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Messenger / metabolism. RNA, Viral / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Epstein Barr Virus, Chronic.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052729.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


100. Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL, Fung H, Krishnan A, Molina A, Nademanee A, O'Donnell M, Popplewell L, Rodriguez R, Forman SJ, Bhatia S: Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol; 2005 Sep 20;23(27):6699-711
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
  • PURPOSE: Autologous hematopoietic cell transplantation (HCT) is being increasingly used as an effective treatment strategy for patients with relapsed or refractory Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) but is associated with therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) as a major cause of nonrelapse mortality.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic System / pathology. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cells / physiology
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Female. Follow-Up Studies. Graft Rejection. Graft Survival. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Staging. Probability. Prospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170178.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5M01 RR00043; United States / NCI NIH HHS / CA / P01 CA30206
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down